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Tramadol hydrochloride is centrally acting analgesic. It is used for the 
management of moderate to severe pain. There are increasing concerns 
worldwide regarding the addiction potential of tramadol. The overall aim of this 
study is to assess the abuse of tramadol among clients who attend private 
psychiatric clinics, by assessing the level of knowledge, attitude, and practice. 
The study also evaluated the psychological status, and the presence of side 
effects related to abuse of tramadol.                       
The design of the study is a descriptive, analytical cross sectional one. 100 clients 
were  selected  from two private psychiatric clinics in Gaza city over one month 
by taking 4 clients every day, the response rate was 83.3. The questionnaire was 
developed to reflect the study domains. Data were collected utilizing the self-
administered questionnaire approach and the reliability coefficient (Cronbach‘s 
Alpha was high 0.8633 the result ensures the reliability of the questionnaire). 
The results of this study showed that 84% of the sample was male and 14% was 
female. They started with 100 mg tramadol capsule daily and increased the dose 
progressively with time until they ended up with around 1800 mg daily, which is 
four times the therapeutic maximum daily dose (400-600 mg daily). This study 
showed that there is clear awareness among the tramadol abusers toward the size 
of problem as 96.4% of the sample believe that the abuse of tramadol is problem 
in Gaza strip, and 94.4% ensured that abuse of tramadol caused addiction. This  
study showed strong association between smoking and tramadol abuse as around 
80% of our sample was smokers. There were various motivations for tramadol 
abuse but the most two common causes were to get euphoria 92.4% and to help 
them to delay ejaculation 79.4%.  The insistent efforts to secure the drug led 
around two thirty (63.4%) of the sample to do illegal action to get the drug. 
Around 76.24% of the sample complained of psychological problem  . Around 
90% of the sample complain of withdrawal symptoms.   Among the various side 
effects convulsion was represented by 71.8% of the sample. There is a  
significant difference at α ≤ 0.05 among the respondents' answers due to 
profession .   
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 Study Goal 
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     There is no doubt that the strength of any society derives from the power of his sons, 
they work as a first line of defense against any breach of the social fabric, by 
maintaining values and morals, religion and heritage. From this standpoint, if spread 
phenomenon of drug and substance abuse among members of the community, 
especially young people, this threatens catastrophe will occur in the community. 
Substance abuse and addictive behavior are universal phenomena and are regarded in 
the twentieth century as a major public health problem . Historical evidence suggest that 
since ancient times living with psychoactive substance seems to be part of the fabric of 
our lives (Gossop,1993). The desire to experience some altered state of unconsciousness 
seems to be an intrinsic part of  the human condition . 
The health and social costs of the abuse of these psychoactive substances unfortunately 
reflect most disturbing morbidity and mortality (Rassool & Gafor, 1997). 
The squealer of the harm physical ,social, psychological and economic derived from the 
abuse of psychoactive substance not only affect the individual user but also the family. 
Following the December 2008 Israeli criminal war, a United Nations survey of Gaza 
residents found increases in risk taking behavior, including a significant rise in cases of 
drug addiction(Hammami, 2009). One drug associated with this trend is Tramadol, first 
developed in Germany during the 1970s and introduced in the 1990s as a centrally 
acting analgesic with properties similar to codeine and morphine and which is widely 
prescribed as a pain killer(Lewis & Han,1997). Although illegal without a prescription 
in some regions, Tramadol is relatively easy to obtain in Gaza, either with fake 
prescriptions from pharmacies or on the black market. News reports prior to the 2008 
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offensive suggested that up to 30 percent of males between the ages of 14 and 30 had 
already been using Tramadol on a regular basis, with some15,000 showing signs of 
addiction(O‘Loughlin, 2008),idly or significant others and the whole community .  
Under the broad ranging and comprehensive Israeli blockade of the Gaza Strip, which 
has been in place since 2007, Gaza society has come to rely heavily on a vast network 
of cross border tunnels, some as much as 18 meters underground, which have become 
crucial supply routes for Palestinians who are cut off from the outside world. Around 
the clock shifts of tunnel workers transport a wide variety of items, from food and 
clothing to household goods and even furniture. Recently, illicit pharmaceuticals and 
other drugs have become hot commodities in the burgeoning tunnel trade. 
The last criminal war against Gaza strip produced a very high degree of comorbidity 
between war-related trauma and depression, along with drug abuse, among Gaza people 
who, have also been psychologically affected by the ongoing war(Bleich, 1997 ). The 
tunnels are the main entry point for Tramadol and other substances into Gaza missed an 
important opportunity to explore drug trafficking as a transnational crime(Chawla S& 
Pietschmann , 2005 ). Although Tramadol is known as Tramal in Gaza and Tramadex in 
Israel, the Palestinian police in Gaza displayed boxes labeled Tramajack, which is the 
name under which tramadol is manufactured in India. The police also showed packets 
of green capsules labeled Tramadol, but which appear to have originated in the 
European Union. Other drugs on display were Proxam, a compound including 
dextropropoxyphene hydrochloride, which is a weak opioid, and Amirol, which is the 





In addition to this phenomena the researcher will concentrate to  assess the abuse  of 
tramadol to identifying the level of knowledge ,attitudes ,and practice ,psychological 
state , and presence of side effects of tramadol abusers. The researcher will take the 
target population of this study from persons who already abuse tramadol and who are 
attending private psychiatric clinics .   
1.2 Statement of the problem 
Drug abuse and addiction has become one of the most important public health problems 
in recent years. Information providing role of lay theories is undeniable in preventive 
and rehabilitative works related to drug addiction. Several studies investigated lay 
beliefs and attitudes related to different kinds of drugs. For instance,( Furnham 
&Thomson, 1996) found that the participants‘ political views were the most important 
determinant of lay beliefs about heroin addiction.  
Research also indicated that certain variables increase the risk of drug abuse. Younger 
people are more prone to drug abuse (Royo-Bordonada et al,1997). 
The increase in abuse of marketed medications in recent years has highlighted the need 
for abuse-liability assessment (Samhsa, 2003). 
The abuse of tramadol among people in the Gaza strip, News reports prior to the 2008 
offensive suggested that up to 30 percent of males between the ages of 14 and 30 had 
Despite consistent border seizures of the smuggled drugs, thousands of boxes of 
Tramadol still make their way to Gaza's who are increasingly dependent on the drug, 
some having become seriously addicted. 
  
1.3 Significance of the study 
Psychoactive substance abuse problems are prevalent and widespread worldwide, and 
are associated with significant morbidity and mortality. The World Health Organization 
(WHO) has identified alcohol, tobacco, and illicit drugs as among the top 20 risk factors 
for ill-health (World Health Organization, 2002) and has adopted as public health 
approach to screening for alcohol and drug abuse, and early intervention for such 
problems (WHO Assist Working Group, 2002). 
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This study shows the importance of the fact  located in the Gaza Strip, about abuse of 
the tramadol.                                                                                  
Because of the spread of tramadol abuse, and the lack of studies around it, and the lack 
of incidence, this is encouraged the researcher to study the phenomena.                         
And also this is the first study of its kind to address the issue of tramadol abuse . This 
study will assess the extent of the phenomenon of abuse of the  tramadol on persons 
who are have tramadol abuse in Gaza strip.                                                                        
                                                                       
 1.4General objective  
This study aims to assess the abuse of Tramadol among persons who have tramadol 
abuse  by examining the level of knowledge, attitude, and practice about the drug. 
1.5 Specific objectives: 
1-To identify the knowledge ,practice , and attitude  of tramadol, among persons who 
abuse tramadol. 
2-To assess the effect of socio demographic factors (age, sex, economic status, level of 
education) on Tramadol abuse. 
3-To assess the effect of psychological stress on abuse of Tramadol . 
4-To assess the side effects of tramadol among Tramadol abusers . 
5-To suggest recommendations for policy and decision makers regarding the 
opportunity to stop tramadol abuse . 
1.6 Research questions  
1- Do the people who abuse Tramadol have any knowledge about Tramadol ? 
2- What is the attitude of persons who have abused Tramadol ? 
3- How do the persons abused Tramadol ? 
4-Does age factor effect on abuse of Tramadol ? 
5-Does the sex factor effect on the abuse of Tramadol ? 
6-Does the marital status factor effect on abused of tramadol ? 
7-Does the kind of occupation factor affect on abused of tramadol ? 
8-Does the economic status factor effect on tramadol abuse ? 
9-Does the abusers complain of any psychological stress ? 




1.7 Context of the study  
The researcher provides an overview about the context where the study was performed 
and variables that influence the topic under the study. The context involves socio-
demographic variables, economic, and  political situation. 
1.7.1 Demographic Context  
Palestine is an Arabic Country, relatively small one. The total surface area of the 
historical Palestine is about 27.000 Km² (Palestine, MOH, 2006). Palestine has been 
occupied in 1948 by Israel and the two remaining parts are separated geographically 
(West Bank and Gaza Strip) after the war in 1967 (Palestine, MOH, 2006). Palestine is 
surrounded by Lebanon, Syria, Jordon, Egypt, and  the Mediterranean Sea. The total 
area of the Gaza Strip(GS) and West Bank is about 6020 Sq. Km with total population 
living in is about 4,108,631 individuals (1,561,906 in GS and 2,546,725 in West Bank) 
with a population density of 682 capita per sq. Km (Palestinian Central Bureau of 
Statistics-PCBS, 2011). 
GS is a narrow piece of land lying on the coast of Mediterranean Sea. The total area of 
the GS is about 365 square kilometer (PCBS, 2011). GS is overcrowded area with total 
population about 1.561.906 with population density of 4279 inhabitants/ Km² and about 
69% of them are refugees as estimated in 2010 (PCBS, 2011).  
GS is divided into five governorates: Gaza Governorates, North Governorates, Mid-
zone Governorate, Khan-Younis Governorate, and Rafah Governorate. 
1.7.2 Socio-economic and Political Context  
The GS undergone a restriction, political and economic closure after the Palestinian 
election in 2006, the conflict between the two main parties Fateh and Hamas resulted in 
a division of control between Palestinian Authority and Hamas government which has 
been complicated by the Israeli closure have had a profoundly negative impact on the 
public health.  
The Israeli war on Gaza in December 2008 through January 2009 resulted in hundreds 
of fatalities and thousands of injuries; and further badly affected the already weakened 
status of the water, sanitation and power sectors in the GS (WB, 2009). The ongoing 
deteriorating economic situations in the GS lead to the rise in the unemployment rate to 
40% in 2008 and 80% of households were living under the poverty line in 2007 
household survey (International Monetary Fund - IMF, 2009).  
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1.8 Operational definitions: 
1.8.1 Tramadol  
Is an effective analgesic in the opioid family that has somewhat lesser narcotic 
associated side effects. 
Tramadol hydrochloride is a widely prescribed, centrally acting analgesic marketed in 
over 90 countries. Before being released in the U.S. in 1995, the drug had been 
available in Europe for almost two decades. Thus, the pharmacokinetic and 
pharmacodynamics properties of tramadol have been extensively investigated. 
Tramadol is a novel centrally acting analgesic used for the treatment of mild to severe 
pain (Clarot F et al,2003). 
Tramadol is an oral analgesic, which stems from both norepinephrine and serotonin 
reuptake inhibition and direct-receptor agonism(C. Hernandez-Lopez et al,2006). 
1.8.2 Substance abuse: 
Refers to the harmful or hazardous use of psychoactive substances, including alcohol 
and illicit drugs(WHO, 2006). 
The DSM defines substance abuse as a pattern of maladaptive substance use that is 
associated with recurrent and significant adverse consequences(DSM-IV). 
1.8.3 Drug misuse  
 Drug misuse is defined as the use of a substance for a purpose not consistent with legal 
or medical guidelines (WHO, 2006). 
1.8.4 Dependence  
 Is defined as a strong desire or sense of compulsion to take a substance, a difficulty in 
controlling its use, the presence of a physiological withdrawal state, tolerance of the use 
of the drug, neglect of alternative pleasures and interests and persistent use of the drug, 
despite harm to oneself and others (WHO, 2006). 
A compulsive pattern of substance use characterized by a loss of control over substance 
use and continued use despite the significant substance-related problems(DSM-IV ). 
 
1.8.5 Drug tolerance  





1.8.6 Depressants  
Are sedatives which act on the nervous system. Artificial relaxation and relief from 
anxiety and mental stress tend to produce psychological dependence and withdrawal 
from heavy use is severe. 
1.8.7 Stimulants  
 are agents that activate, enhance, or increase neural activity. They include 
amphetamines and synthetic appetite suppressants such as phenmetrazine or 
methylphenidate. They can give rise to symptoms suggestive of intoxication, including 
tachycardia, pupillary dilation, elevated blood pressure, nausea or vomiting and 
abnormal behavior such as fighting. agitation and impaired judgment. A full-blown 
delusional psychosis may occur . 
1.8.8 Hallucinogens  
Are a chemically divers group which produce profound mental changes such as 
euphoria, anxiety, sensory distortion, hallucination, delusion, paranoia and depression. 
They include mescaline and LSD. 
 
1.8.9 Tramadol abuse 
From the view point of the researcher tramadol abuse can be defined as use of tramadol 












 Theoretical Framework   
o Drug Abuse 
o Tramadol 



















The term opioids refers to a class of psychoactive substances derived from the poppy 
plan including opium, morphine and codeine, as well as semi-synthetic forms including 
heroin and synthetic compounds including methadone and buprenorphine with similar 
properties (WHO, 2006). Illicit use of opioids generally involves injecting, or inhaling 
the fumes produced by heating the drug. The term opiate refers strictly to the subset of 
opioids that are naturally occurring or semi-synthetic, and therefore includes heroin and 
morphine but excludes methadone and buprenorphine. 
Stimulants refer broadly to any substance that activates, enhances or increases neural 
activity (WHO,2006) . Illicit stimulants include cocaine, crack cocaine and 
amphetamines. Cocaine is one of the most commonly abused illicit stimulants in the 
Europe  (Roe & Man, 2006). It is extracted from the leaf of the coca plant and generally 
sniffed in powder form. Crack cocaine is usually smoked but sometimes injected. 
Amphetamines are a group of synthetic substances with different chemical structures 
but broadly similar stimulant properties to cocaine, and include dexamphetamine 
sulphate a prescription drug licensed for the treatment of narcolepsy and attention-
deficit hyperactivity disorder but which has misuse potential) and methamphetamine. 
Cannabis is a generic term denoting the various preparations of the cannabis sativa 
plant, including cannabis leaves the most common form, which is smoked, hashish resin 
and the rarely used cannabis oil. Tetrahydrocannabinol is the key constituent of 
cannabis that produces the psychoactive effect sought by most users, and the different 
forms of cannabis vary in their tetrahydrocannabinol content (WHO, 2006). 
Drug misuse is defined as the use of a substance for a purpose not consistent with legal 
or medical guidelines (WHO, 2006). It has a negative impact on health or functioning 
and may take the form of drug dependence, or be part of a wider spectrum of 
problematic or harmful behavior (DH, 2006). 
The Advisory Council on the Misuse of Drugs (ACMD) characterizes problem drug use 
as a condition that may cause an individual to experience social, psychological, physical 
or legal problems related to intoxication and regular excessive consumption, and 
dependence (ACMD, 1998). 
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2.1.2 Drug dependence 
Dependence is diagnosed according to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV) when three or more of the following criteria are present in a 12-
month period: tolerance; withdrawal; increasing use over time; persistent or 
unsuccessful attempts to reduce use; preoccupation or excessive time spent on use or 
recovery from use; negative impact on social, occupational or recreational activity; and 
continued use despite evidence of its causing psychological or physical problems 
(American Psychiatric Association [APA], 1994). 
The diagnosis of dependence is clearest with opioids. The WHO states that: 
‗opioid dependence develops after a period of regular use of opioids, with the time 
required varying according to the quantity, frequency and route of administration, as 
well as factors of individual vulnerability and the context in which drug use occurs. 
Opioid dependence is not just a heavy use of the drug but a complex health connotation 
that has social, psychological and biological determinants and consequences, including 
changes in the brain. It is not a weakness of character or will (WHO, 2006). 
However, dependence, as characterized by the above definition, can also occur with 
stimulants and cannabis. 
2.1.3Tolerance 
Repeated use of a drug can lead to the development of tolerance in which increased 
doses of the drug are required to produce the same effect. Tolerance develops to 
opioids, stimulants and cannabis. Cessation of use leads to reduced tolerance and this 
may present significant risks for individuals who return to drug doses at a level to which 
they had previously developed tolerance. This can result in accidental overdoses and, in 
the case of opioid misuse, could lead to respiratory depression and death. 
2.1.4Withdrawal 
Withdrawal syndromes have clearly been identified after cessation or reduction of 
opioid and stimulant use. DSM-IV criteria for a withdrawal disorder include the 
development of a substance-specific syndrome due to cessation or reduction in use; the 
syndrome causing clinically significant distress; and symptoms not due to a general 
medical condition or better explained by another mental disorder (APA, 1994). While 
withdrawal effects have been associated with cessation of heavy opioid use, their 
clinical significance is uncertain at present (Budney et al., 2004). 
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People who abuse drugs may present with a range of health and social problems other 
than dependence, which may include (particularly with opioid abusers): 
 physical health problems (for example, thrombosis, abscesses, overdose, hepatitis 
B and C, HIV, and respiratory and cardiac problems). 
 mental health problems (for example, depression, anxiety, paranoia and suicidal 
thoughts). 
 social difficulties (for example, relationship problems, financial difficulties, 
unemployment and homelessness). 
 criminal justice problems. 
Many people who abuse drugs use a range of substances concurrently and regularly 
known as polydrug abuse. The use of opioids alongside cocaine or crack cocaine is 
common, with the National Drug Treatment Monitoring System (NDTMS), which 
collects, collates and analyses information from those involved in the drug treatment 
system, reporting an increase in the use of both drugs, from 18% of those presenting for 
drug treatment in 1998 to 24% in 2001 National Treatment Agency for Substance 
Misuse (NTA, 2005). Alcohol abuse is also common in all types of people who misuse 
drugs; data from the National Treatment Outcomes Research Study (NTORS) on drug 
misuse suggested that 22% of participants also drank alcohol frequently, 17% drank 
extremely heavily and 8% drank an excessive amount on a daily basis (Gossop et al., 
2000). People who misuse opioids in particular may often take a cocktail of substances, 
including alcohol, cannabis and prescribed drugs such as benzodiazepines, which can 
have especially dangerous effects in comparison with one of the drugs taken 
individually. 
The association between drug misuse and crime also applies in the younger population., 
The Home Office 2004 Offending Crime and Justice Survey (The Information Centre, 
Lifestyle Statistics, 2006) found that young people who had used drugs in the past year 
were over twice as likely to have committed an offence compared with those who 
reported not having used drugs (52% versus 19%). In addition, young offenders who 
had taken a Class A drug in the past year were more likely to be frequent offenders than 
those who reported using other types of drugs. However, in contrast to figures for the 
general population, Class A drug users comprise a very small proportion (1% testing 
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positive for heroin and 4% for cocaine) of arrestees aged below 18 years (Matrix 
Research and Consultancy & Institute for Criminal Policy Research, 2007). 
2.1.5Etiology and maintenance of drug abuse 
Drug abuse is increasingly portrayed in the field as a medical disorder known as the 
disease model of drug misuse or abuse, in part due to advances in our understanding of 
the neurobiology underlying dependence (Volkow & Li, 2005). There is also no 
question that numerous socioeconomic and psychological factors all play an important 
part in the etiology of drug abuse. These conceptualizations are not mutually exclusive; 
rather they are facets of the multifactorial a etiology of drug abuse . 
The most robust evidence highlights peer drug use, availability of drugs and also 
elements of family interaction, including parental discipline and family cohesion, as 
significant risk factors for drug misuse (Frischer et al., 2005). In particular, traumatic 
family experiences such as childhood neglect, homelessness or abuse increase the 
likelihood that the individual will develop problems with drugs later on in life (Kumpfer 
& Bluth, 2004). Recent studies of twins, families and people who have been adopted 
suggest that vulnerability to drug abuse may also have a genetic component (Prescott et 
al., 2006), although it is unclear whether repeated use is primarily determined by 
genetic predisposition, or socioeconomic and psychological factors lead an individual to 
try and then later to use drugs compulsively. Risk factors for heavy, dependent drug use 
are much more significant when they occur together rather than individually. 
A defining characteristic of drug dependence is that drug use begins as a voluntary 
action to seek a rewarding stimulus, but continued use results in loss of control over the 
use, despite its negative consequences (Dackis & O‘Brien, 2005). The effects of many 
illicit drugs are mediated via various brain circuits, in particular the mesolimbic 
systems, which have evolved to respond to basic rewards such as food and sex to ensure 
survival. A diverse range of substances, including opioids, stimulants and cannabis, as 
well as alcohol and nicotine, all appear to produce euphoric effects via increasing levels 
of dopamine a neurotransmitter in the nucleus accumbens (Dackis & O‘Brien, 2005). 
This has been well demonstrated in human brain-imaging studies (Volkow et al., 1999). 




Chronic drug use may produce long-lasting changes in the reward circuits, including 
reductions in dopamine receptor levels (Volkow et al., 1999), and these contribute to 
the clinical course of drug dependence, including craving, tolerance and withdrawal 
(Lingford-Hughes & Nutt, 2003). 
In addition, other types of neurotransmitter systems for example, opioids, glutamates 
and cannabinoids are implicated in the abuse of specific drugs. 
Although initiation into drug use does not lead inevitably to regular and problematic use 
for many people (Anthony et al., 1994), it is clear that when use begins, it often 
escalates to abuse and sometimes to dependence tolerance, withdrawal symptoms and 
compulsive drug taking. Once dependence is established, particularly with opioids, 
there may be repeated cycles of cessation and relapse extending over decades (National 
Consensus Development Panel on Effective Medical Treatment of Opiate Addiction, 
1998). Vulnerability to use is highest among young people, with most problem drug 
users initiating by the age of 20. 
Individuals dependent on drugs often become so in their early twenties and may remain 
intermittently dependent for many years. 
With cannabis and cocaine, recreational use is more common and it is likely that there 
are different patterns of use, with those taking cocaine being divided between those who 
take the drug on an episodic basis and those who take it daily; in contrast, usually only a 
small number of people taking cannabis move to repeated daily increasingly heavy use, 
with many taking the drug intermittently. A general US population survey of 8,098 
individuals (Anthony et al., 1994) found that among those who had used cocaine or 
cannabis in their lifetime, 16.7% and 9.1% subsequently became dependent on the 
respective drugs; for heroin, Such differences may relate to the different intensities of 
action different drugs produce within the neural reward sites (Stimmel & Kreek, 2000). 
The neurobiological account of fundamental reward systems implicated in drug abuse 
may parallel the sociocultural–behavioral–cognitive model presented by Orford (2001). 
He conceptualized drug abuse as an excessive appetite , belonging to the same class of 
disorders as gambling, eating disorders and sex addiction. All involve activities that 
form strong attachment, and were once rewarding, but with excessive consumption 
result in compulsion and negative consequences. Orford argued that the emotional 
regulation of such appetitive behaviors in their respective social contexts for example, 
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the excitement associated with gambling or the anticipation of the next ‗fix‘ of heroin, 
well characterized within the principles of operant conditioning, is a primary factor 
driving excessive use. Secondary factors such as internal conflict knowing that the 
behavior is harmful yet being unable to disengage from it potentiate these emotions and 
thus excessive use, but an alternative result is that the individual alters behavior in order 
to resolve such conflict. This crucially suggests that recovery is not impossible, but also 
that successful treatment attempts are likely to operate against a background of 
powerful natural processes (Orford, 2001). 
 
2.1.6The sequence of drug abuse 
Drug abuse is a relapsing and remitting condition often involving numerous treatment 
episodes over several years (Marsden et al., 2004). While the initiation of drug use does 
not lead inevitably to dependence over the long term (Anthony & Petronis, 1995), a 
number of factors can potentiate this developmental course. Earlier initiation of drug 
use increases the likelihood of daily use, which in turn results in a greater likelihood of 
dependence (Kandel et al., 1986). 
Among people who misuse opioids, who form the predominant in-treatment population, 
most individuals develop dependence in their late teens or early twenties, several years 
after first using heroin, and continue using over the next 10–30 years. In a long-term 
outcome study up to 33 years of 581 male opioid users in the US, 30% had positiveor 
refused urine tests for opioids, 14% were in prison and 49% were dead (Hser et al., 
2001). Longitudinal data from the US also showed that the average time from first to 
last opioid use was 9.9 years, with 40% dependent for over 12 years (Joe et al., 1990). 
Although it is the case that problem drug users can cease drug use without any formal 
treatment (Biernacki , 1986), particularly for individuals with primary cocaine or 
cannabis misuse, for many it is treatment that alters the course of opioid dependence. 
Most initiation of cocaine use occurs around the age of 20, with the risk of cocaine 
dependence occurring early and explosively after first use, and persisting for an average 
of 10 years (Anthony et al., 1994). 
Cannabis use typically begins in early adolescence with heaviest use in the 15–24 age 
group (Harkin et al., 1997), which may in part be explained by strong peer influences 
(Frischer et al., 2005). Most use tends to decline steadily from the mid-20s to the early 
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30s (Bachman et al., 1997). Cannabis dependence persisting through adulthood is the 
most prevalent among those with sustained frequent use, as high as 40% among those 
who have used almost daily (Kandel & Davies, 1992). 
Although drug abuse can affect all socioeconomic groups, deprivation and social 
exclusion are likely to make a significant contribution to the maintenance of drug abuse  
(ACMD,1998) . That said, an association has been found between income in 
adolescence and early adulthood and cannabis use (Makkai & McAllister, 1997), which 
may reflect the recreational nature of the majority of cannabis use. 
Factors that influence the cessation of drug use in adulthood are similar to those 
associated with lack of drug use in adolescence. For example, transitions into social 
roles with greater conventionality, responsibility and contexts that are not favorable to 
using drugs such as employment, marriage and pregnancy; for example, ( Bachman et 
al., 1997) and good health are not associated with long-term use. Peer pressure is a 
major influence on experimental use and is also likely to affect a move towards regular 
use. The level of drug use is again a clear predictor of continued use. 
Once an individual is dependent, drug use is generally a chronic condition, interspersed 
with periods of relapse and remission (Marsden et al., 2004). Repeated interaction with 
the criminal justice system, long-term unemployment and increasing social isolation 
serve to further entrench drug use. 
 
2.1.7 THEORETICAL REVIEW ON SUBSTANCE ABUSE  
2.1.7.1 Expectancy Model 
This theory evolved from cognitive-behavioral and social learning perspectives (Dimeff 
& Marlatt, 1998). According to this model, people with alcohol dependence develop 
problematic beliefs about substances use relatively early in life can occur through a 
combination of reinforcement and observational learning  
Another concept of expectancy model is that of self- efficacy and coping. Self-
expectancy refers to an individual‘s perception that he or she has the ability to meet the 
challenges of a difficult situation while coping refers to the strategies that an individual 
uses to reduce the perception of a threat or danger.  
Based on Dimeff and Marlatt‘s (1988) expectancy model, a series of reactions can occur 
when a drug-dependent individual attempts to remain abstinent. There will be a 
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contrasting scene when two persons try to remain abstinent in high-risk situations. For 
example, Persons A and B encountered high-risk situations, such as parties where 
people are consuming alcohol. ―A‖ is able to abstain from drinking at the party because 
he or she has learned how to cope with such situations, and he or she feels capable of 
carrying through with his or her intention not to drink alcohol. Each successful episode 
of abstinence reinforces his or her sense of self-efficacy, causing him or her to feel more 
capable of abstaining in subsequent situations. ―B‖ lacks a satisfactory coping response. 
The actual consumption of alcohol is not what leads to a relapse, but, rather, his or her 
interpretation of the act of drinking as a sign of loss of self-control.  
Thus, when ―B‖ enters a high-risk situation, he or she feels incapable of staying away 
from alcohol because of his or her low sense of self-efficacy. A compelling expectation 
that alcohol will have a positive mood-altering effect adds to his or her low sense of 
self-efficacy and leads him or her to take the first drink.  
The positive sensations that the drug produces further undermine ‗B‘s resolve, but 
cognitive factors enter at this point in the process as well. Having violated the self-
imposed rule of remaining abstinent, ―B‖ now is subject to the abstinence violation 
effect, a sense of loss of control over one‘s behavior that has an overwhelming and 
demoralizing effect. Thus, ‗B‘s self-efficacy is further eroded, initiating a down-ward 
spiral trend, which eventually ends in renew drug dependence. 
2.1.7.2 Eysenck’s Personality Theory  
Hans Eysenck, a trait theorist (1916-1997), defined personality as the sum total of the 
actual or potential behaviour pattern of the organism, as determined by hereditary and 
environment and traits as enduring characteristics within individual that determines his 
or her behaviour. Employing factor analysis he concluded that, traits can be subsumed 
under three basic types:  
(1) Introversion-Extraversion . 
(2) Neuroticism . 
 (3) Psychoticism. 
2.1.7.2.1 Personality and Substance abuse  
Personality variables help to explain why certain people are drawn to substance abuse. 
In this regard, researchers have studied high levels of negative affect and an enduring 
desire for arousal and increased positive affect. In one study (Davison & Neale, 2001), 
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kindergarten children were rated by their teachers on several personality traits and were 
followed up several years later. Anxiety (e.g., worries about things, fear of new things 
or situations) and novelty seeking (e.g., restlessness, forgetting) predicted the onset of 
getting drunk, using drugs, and smoking (Killen et al, 1997). Drug use in general has 
been found to correlate with anti-social personality disorder (Ball, Carroll, & 
Rounsaville, 1994). Rebelliousness and high levels of aggression have been found to be 
related to substance abuse (Anderson et al, 1997; Davison & Neale, 2001).  (Lavelle, 
Hammersley, & Forsyth, 1991) showed that drug user were shrewd, tough-minded, 
anxious, streetwise and experience-seeking. Further, Ekstrand (1985) reported that drug 
users seemed to be immature, compulsive and possess low self-esteem and are 
incapable of managing failure. Also Shedler & Block (1990) indicate that frequent drug 
users were maladjusted, socially alienated, and deficient in impulse control and 
manifestly distressed. Conversely, abstainers were observed to be anxious, emotionally 
constricted and lacking in social skills.  
With respect to extraversion, findings on its relationship with substance abuse have 
been mixed. Eysenck‘s (1967) arousal theory categorized it on the bases of stimulation, 
excitement and gregariousness and these are potent factors in predicting drug use. 
Furthermore, Oluwatelure (1995) found a positive relationship between extraversion 
and alcohol abuse. However, Ifeagwazi‘s (2005) study failed to find a positive 
relationship between extraversion and drug use. The researcher explained the result by 
suggesting that extraversion is not a pronounced personality trait that distinguishes drug 
users from non-users. However, it seems that extraversion is a more positively valued 
personality trait (than introversion) and thus is not likely to be higher among drug users 
than in the general population.  
With respect to neuroticism, studies have found a strong relationship between it and 
substance abuse. Neuroticism reflects individual differences in the extent to which a 
person perceives and experiences the world as problematic, threatening and distressing. 
High scorers on this scale experience various negative emotions such as anxiety, guilt, 
sadness, and hostility. They tend to feel inadequate and inferior and report elevated 
level of stress and indicate that they cope poorly with stress, causing pronounced 
emotional liability (Watson, Clark, & Harkness, 1994).  
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The experience of negative unpleasant states, has been linked with alcohol and drug use 
(Ifeagwazi; 2005). Pharmacological evidence indicates that opiates and tranquilizers are 
used more frequently by anxious and neurotic persons to reduce their emotional distress. 
In fact, emotional instability including frustration, anxiety, depression and unhappiness 
has become crucial in etiological explanations of substance abuse (Kuna & Bande, 
1993) for instance; anger or unhappiness is related to cigarette smoking and alcohol use.  
With reference to psychoticism, studies have repeatedly shown a positive relationship 
between psychoticism and substance abuse. High scorers on the psychoticism scale 
exhibit some personality and behavioral traits e.g., aggressiveness, impulsivity, 
egocentrism; and impersonal feelings and anti-social tendencies (Carey & dilalla, 1994); 
these are linked with the initiation and maintenance of drug use (Anderson et al, 1997). 
 
2.2 The Pharmacological Effects Of Drug Abuse  
2.2.1 Opioids 
Opioids have many effects on the brain, mediated through specific receptors (μ, κ, or δ). 
The key opioid receptor subtype is μ, which mediates ‗euphoria‘, as well as respiratory 
depression, and is the main target for opioids (Lingford-Hughes & Nutt, 2003), while 
the κ receptor is involved in mood regulation. Drugs such as heroin and methadone are 
agonists, which stimulate the receptor. Buprenorphine is a partial agonist; that is, it 
occupies the receptor in the same way but only partially activates it. In addition, it is an 
antagonist at the κ receptor and therefore is less likely to lower mood compared with μ 
agonists. 
Soon after injection or inhalation, heroin metabolizes into morphine and binds to opioid 
receptors. This is subjectively experienced as a euphoric rush, normally accompanied by 
a warm flush, dry mouth, and sometimes nausea, vomiting and severe itching. As the 
rush wears off, drowsiness, and slowing of cardiac function and breathing (sometimes 
to the point of death in an overdose), persist for several hours (National Institute on 
Drug Abuse [NIDA], 2005). The effects of methadone are similar but more drawn out 
and therefore less intense lasting up to 24 hours when taken orally as prescribed; 
however, this may be circumvented by illicit users who inject the drug. 
The most obvious consequence of long-term opioid use is the development of opioid 
dependence itself, and the associated harms. Repeated injection will also have medical 
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consequences, such as scarring, infection of blood vessels, abscesses, and compromised 
functioning of the kidney, liver and lungs (with increased vulnerability to infections). 
2.2.2 Stimulants 
As central nervous system stimulants, cocaine and amphetamine affect a number of 
neurotransmitter systems in the brain but exert their effects primarily via dopamine, 
which mediates reward. Cocaine blocks the presynaptic reuptake of dopamine, such that 
it is not removed from the intracellular space and leads to extended firing of 
postsynaptic neurons, resulting in physiological arousal. Amphetamines also increase 
the availability of dopamine but are thought to do so by triggering a presynaptic 
leakage. 
The acute subjective effects of cocaine are euphoria, increased energy, heightened 
alertness, sexual arousal, increased sociability and talkativeness. Physiologically there 
can be acute adverse effects on breathing, and the cardiovascular and central nervous 
systems: increased heart rate, blood pressure and body temperature, and pupil dilation. 
All these effects have near-immediate onset but also diminish quickly (after roughly 
15–30 minutes if the drug is snorted and 5–10 minutes if smoked), as cocaine is 
metabolized rapidly by the body (NIDA, 2004). As acute effects wear off, users 
experience a rebound period crash, which may include restlessness, anxiety, agitation 
and insomnia. This can lead to the user bingeing on cocaine in an attempt to displace 
these negative effects. Chronic misuse of cocaine may lead to increased paranoia, 
inability to concentrate, sexual dysfunction and cognitive deficits. 
For amphetamines, the acute effects are broadly similar except that they are long lasting 
(normally 4–8 hours), due to slower metabolism. Overdoses may lead to dangerously 
elevated body temperature, convulsions or even death. Chronic misuse may cause long-
term damage to the brain‘s ability to manufacture dopamine, possibly resulting in 
amphetamine psychosis. 
2.2.3 Cannabis 
Cannabis affects almost every body system, via cannabinoid receptors in the brain, 
which regulate a range of cognitive and motor functions (NIDA, 2005b). Within 
minutes of smoking cannabis, the heart rate increases and the bronchial passages relax. 
Often the individual experiences intoxication, mild euphoria and increased sociability. 
However, anxiety or paranoia may sometimes occur, particularly among first-time or 
20 
 
psychologically vulnerable users (Johns, 2001). Distorted perceptions are common, for 
example colors may appear more intense and time may seem to slow down. The 
euphoria reaches a plateau lasting 2 hours or more, depending on the dose, after which 
the individual may feel sleepy or depressed. 
Cannabis use also impairs memory, attention and motor coordination, with especially 
dangerous consequences on driving performance. Such effects may last for many hours 
after administration of the drug; the numerous metabolites of a single moderate dose of 
cannabis may require up to 4 weeks to be completely eliminated from the body 
(Maykut, 1985). The smoke from cannabis contains the same constituents as tobacco 
smoke; hence chronic cannabis smoking is associated with a range of respiratory tract 
disorders, including bronchitis, emphysema and cancers (Hashibe et al., 2005; Tashkin, 
1990). 
2.3DSM-IV Substance Abuse Criteria  
Substance abuse is defined as a maladaptive pattern of substance use leading to 
clinically significant impairment or distress as manifested by one (or more) of the 
following, occurring within a 12-month period:  
1. Recurrent substance use resulting in a failure to fulfill major role obligations at 
work, school, or home (such as repeated absences or poor work performance 
related to substance use; substance-related absences, suspensions, or expulsions 
from school; or neglect of children or household).  
2. Recurrent substance use in situations in which it is physically hazardous (such as 
driving an automobile or operating a machine when impaired by substance use)  
3. Recurrent substance-related legal problems (such as arrests for substance related 
disorderly conduct)  
4. Continued substance use despite having persistent or recurrent social or 
interpersonal problems caused or exacerbated by the effects of the substance (for 
example, arguments with spouse about consequences of intoxication and 
physical fights).  
Note: The symptoms for abuse have never met the criteria for dependence for this class 
of substance. According to the DSM-IV, a person can be abusing a substance or 
dependent on a substance but not both at the same time.  
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2.4 DSM-IV Substance Dependence Criteria 
Substance dependence is defined as a maladaptive pattern of substance use leading to 
clinically significant impairment or distress, as manifested by three (or more) of the 
following, occurring any time in the same 12-month period:  
1. Tolerance, as defined by either of the following: (a) A need for markedly 
increased amounts of the substance to achieve intoxication or the desired effect 
or (b) Markedly diminished effect with continued use of the same amount of the 
substance.  
2. Withdrawal, as manifested by either of the following: (a) The characteristic 
withdrawal syndrome for the substance or (b) The same (or closely related) 
substance is taken to relieve or avoid withdrawal symptoms.  
3. The substance is often taken in larger amounts or over a longer period than 
intended.  
4. There is a persistent desire or unsuccessful efforts to cut down or control 
substance use.  
5. A great deal of time is spent in activities necessary to obtain the substance, use 
the substance, or recover from its effects.  
6. Important social, occupational, or recreational activities are given up or reduced 
because of substance use.  
7. The substance use is continued despite knowledge of having a persistent 
physical or psychological problem that is likely to have been caused or 
exacerbated by the substance (for example, current cocaine use despite 
recognition of cocaine-induced depression or continued drinking despite 
recognition that an ulcer was made worse by alcohol consumption).  
2.5 ICD-10 Clinical description 
A cluster of physiological, behavioral, and cognitive phenomena in which the use of a 
substance or a class of substances takes on a much higher priority for a given individual 
than other behaviors that once had greater value. A central descriptive characteristic of 
the dependence syndrome is the desire (often strong, sometimes overpowering) to take 
psychoactive drugs (which may or may not have been medically prescribed), alcohol, or 
tobacco. There may be evidence that return to substance use after a period of abstinence 
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leads to a more rapid reappearance of other features of the syndrome than occurs with 
nondependent individuals. 
2.5.1 ICD-10 Diagnostic guidelines  
A definite diagnosis of dependence should usually be made only if three or more of the 
following have been present together at some time during the previous year: 
 A strong desire or sense of compulsion to take the substance; 
 Difficulties in controlling substance-taking behavior in terms of its onset, 
termination, or levels of use; 
 A physiological withdrawal state when substance use has ceased or have been 
reduced, as evidenced by: the characteristic withdrawal syndrome for the 
substance; or use of the same (or closely related) substance with the intention of 
relieving or avoiding withdrawal symptoms; 
 Evidence of tolerance, such that increased doses of the psychoactive substance 
are required in order to achieve effects originally produced by lower doses (clear 
examples of this are found in alcohol- and opiate-dependent individuals who 
may take daily doses sufficient to incapacitate or kill non tolerant users); 
 Progressive neglect of alternative pleasures or interests because of psychoactive 
substance use, increased amount of time necessary to obtain or take the 
substance or to recover from its effects; 
 Persisting with substance use despite clear evidence of overtly harmful 
consequences, such as harm to the liver through excessive drinking, depressive 
mood states consequent to periods of heavy substance use, or drug-related 
impairment of cognitive functioning; efforts should be made to determine that 
the user was actually, or could be expected to be, aware of the nature and extent 
of the harm. 
2.5.2 ICD-10 Diagnostic criteria for research 
Three or more of the following manifestations should have occurred together for at least 
1 month or, if persisting for periods of less than 1 month, should have occurred together 
repeatedly within a 12-month period: 
 A strong desire or sense of compulsion to take the substance; 
 Impaired capacity to control substance-taking behavior in terms of its onset, 
termination, or levels of use, as evidenced by the substance being often taken in 
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larger amounts or over a longer period than intended, or by a persistent desire or 
unsuccessful efforts to reduce or control substance use.  
 A physiological withdrawal state when substance use is reduced or ceased, as 
evidenced by the characteristic withdrawal syndrome for the substance, or by use 
of the same (or closely related) substance with the intention of relieving or 
avoiding withdrawal symptoms. 
 Evidence of tolerance to the effects of the substance, such that there is a need for 
significantly increased amounts of the substance to achieve intoxication or the 
desired effect, or a markedly diminished effect with continued use of the same 
amount of the substance. 
 Preoccupation with substance use, as manifested by important alternative 
pleasures or interests being given up or reduced because of substance use; or a 
great deal of time being spent in activities necessary to obtain, take or recover 
from the effects of the substance. 
 Persistent substance use despite clear evidence of harmful consequences as 
evidenced by continued use when the individual is actually aware, or may be 
expected to be aware, of the nature and extent of harm. 
2.6 The public health impact of drug abuse   
The harms associated with illicit drugs use include increased mortality from overdose 
and from other directly or indirectly associated harms such as increased risk of infection 
with blood-borne viruses HIV, hepatitis B and hepatitis C; high levels of depression and 
anxiety disorders; social problems such as disrupted parenting, employment and 
accommodation; and increased participation in income-generating crime. 
(Oppenheimer et al., 1994) and 22 times (Frischer et al., 1997) that of the general 
population. In England and Wales, there were 1,382 drug-related deaths in 2005 
(National Programme on Substance Abuse Deaths, 2005). The majority (59%) were 
cases of accidental poisoning, although a sizeable proportion (16%) was a result of 
intentional self-poisoning. Opioids alone or in combination with other drugs accounted 
for some 70% of the deaths, and cocaine 13%. Many of the deaths appear to be due to 
multiple drug toxicity, especially the presence of central nervous system depressants for 
example, alcohol and benzodiazepines, rather than simply an overdose of an opioid. 
This is supported by research that shows those whose deaths were attributed to overdose 
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have opioid levels no higher than those who survive, or than heroin users who die from 
other causes (Darke & Zador, 1996). Recent cohort studies have shown that mortality 
rates from methadone-related death are decreasing (Brugal et al., 2005). 
Psychiatric comorbidity is common in drug abuse populations, with anxiety and 
depression generally common, and antisocial and other personality disorders in opioid-
using populations (Regier et al., 1990, 1998). The national US Epidemiological 
Catchment Area study of the prevalence of mental health disorders reported a 47% 
lifetime prevalence rate of substance abuse drugs and alcohol among people with 
schizophrenia compared with 16% in the general population, and found that more than 
60% of people with a diagnosis of bipolar I disorder had a lifetime diagnosis of 
substance misuse disorder. Around one in five of the people in the NTORS sample had 
previously received treatment for a psychiatric health problem other than substance 
misuse (Marsden et al., 2000). Drug misuse disorders complicated by other comorbid 
mental disorders have been recognized as having a poorer prognosis and being more 
difficult to treat than those without comorbid disorders; comorbid disorders are more 
likely to be chronic and disabling, and result in greater service utilization. 
Lost productivity and unemployment increase with the severity and duration of drug 
misuse, and personal relationships are placed under considerable strain by dependent 
drug use. Problems with accommodation are also common in such groups. For example, 
prior to intake in the NTORS, 7% of the study group were homeless and living on the 
street, 5% were living in squats and 8% were living in temporary hostel accommodation 
(Gossop et al., 1998). 
Drug abuse  may also have a negative impact on children and families (ACMD, 2003). 
In Gaza there is no prevalence or incidence data of drug abuse in general ,and tramadol 
abuse particularly . 
   
2.7 The aims of treatment of drug abuse  
The clinical management of drug abuse may be categorized into three broad 
approaches: harm reduction, maintenance-oriented treatments and abstinence-oriented 
treatments. All treatments aim to prevent or reduce the harms resulting from use of 





2.7.1Harm reduction  
Aims to prevent or reduce negative health or other consequences associated with drug 
abuse, whether to the drug-using individual or, more widely, to society. With such 
approaches, it is not essential for there to be a reduction in the drug use itself although, 
of course, this may be one of the methods of reducing harm. For instance, needle and 
syringe exchange services aim to reduce transmission of blood-borne viruses through 
the promotion of safer drug injecting behavior. 
 
2.7.2Maintenance 
In the who context primarily refer to the pharmacological maintenance of people who 
are opioid dependent, through the prescription of opioid substitutes (methadone or 
buprenorphine). This therapy aims to reduce or end their illicit drug use and the 
consequential harms. 
2.7.3 Abstinence 
Aim to reduce an individual‘s level of drug use, with the ultimate goal of abstinence. 
The NTORS found that approximately one third of those entering treatment services 
were abstinent 5 years later (Gossop et al., 2003). However, these treatments may be 
associated with an increased risk of death from overdose in the event of relapse after a 
period of abstinence, during which time drug tolerance is lost (Verger et al., 2003). 
Consequently, it is particularly important for abstinence oriented treatment to include 
education on post-detoxification vulnerability to relapse (Gossop et al., 1989) and to 
overdose, and for wider psychosocial rehabilitation support to be provided. 
The clinical management of drug abuse may be categorized into three broad 
approaches: harm reduction, maintenance-oriented treatments and abstinence-oriented 
treatments. All treatments aim to prevent or reduce the harms resulting from use of 
drugs. Care planning and key working should form a core part of subsequent treatment 
and care. 
2.7.4 Care planning  
Should consider the following when any treatment or management plan is developed: 
 type and pattern of use 
 level of dependence 
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 comorbid mental and physical health problems 
 setting 
 age and gender 
 service user‘s aspirations and expectations. 
The general principles of treatment are that no single treatment is appropriate for all 
individuals, treatments should be readily available and begin when the service user 
presents, and there should be the capacity to address multiple needs. It is also 
accepted that treatments will change over time. It appears that treatment does not 
need to be voluntary to be successful – comparisons of voluntary and legally 
coerced drug treatment have been reviewed recently elsewhere (NCCMH, 2008). 
For most people in long-term treatment, that is those with opioid dependence, 
substitute medications, such as methadone and buprenorphine, are important 
elements of care. However, services also need to address coexisting problems, such 
as mental health and physical health problems, alongside the drug misuse. 
 
2.7.5Continous practice 
Only a minority entering treatment initially chooses abstinence and enforced abstinence 
appears ineffective. However, approximately one third entering treatment services 
generally are abstinent 5 years later at least for a period of time (Gossop et al., 1998). 
The most common types of psychosocial interventions programmed specifically 
targeting drug-use behaviors might be based on one of a number of models, including 
cognitive-behavioral for example, motivational interviewing and relapse prevention, 
humanistic and 12-step approaches (Wanigaratne et al. 2005). Often this is unfocused, 
and therapist and client may not have a clear understanding of the therapeutic goals or 
therapeutic method. In addition, there exist formal psychological therapies delivered 
within adult mental health settings, aiming to address drug users coexisting mental 
health problems (NTA, 2006). 
Brief interventions, typically empathic in nature and lasting up to two sessions, have a 
variety of potential advantages in the treatment of drug misuse, including ease of 
delivery and retention of drug users. These interventions can be conducted in a variety 
of settings, opportunistically to people not in formal drug treatment and as an adjunct to 
formal, structured drug treatment (Ashton, 2005). Although brief interventions are 
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considered to be an important component of psychosocial treatment in open-access drug 
services (NTA, 2002., NTA, 2006). 
 
2.8 Drug Abuse And The Family  
In the literature, drug abuse is seen as both a problem of the family and a problem for 
the family‘ (Bancroft et al., 2002). The evidence that points to traumatic family 
experiences, such as childhood neglect, homelessness, abuse, loss and bereavement, 
increasing the likelihood that a person will go on to have drug problems (Kumpfer & 
Bluth, 2004) can be seen as a problem of the family. 
As 60–80% of people who abuse drugs live or are in regular contact with their family 
(Stanton & Heath, 2005), and approximately 2–3% of all children under the age of 16 
years have parents with a drug problem (ACMD, 2003), drug abuse can also be said to 
be a problem for the family. The impact may be psychological for example, depression 
and anxiety, physical raised blood pressure and ulcers (Velleman et al., 1993), social 
feelings of isolation and work, family and social difficulties (Hudson et al., 2002) and 
financial. 
Appropriate involvement of family members and careers in the assessment and 
treatment process may also support the family member/career and facilitate a more 
successful outcome for the user. There is evidence that families including parents, 




Tramadol is a novel centrally acting analgesic used for the treatment of mild to severe 
pain (Clarot F et al., 2003). It has been approved in some countries since 1980 and 
become the most prescribed opioid worldwide(Loughrey et al.,2003).                               
Selecting Committee in 2002 as an analgesic. During this period, it has been abused 
especially by the younger population. Tramadol binds weakly to the μ-opioid receptor 
and also inhibits reuptake of monoamines such as serotonin and norepinephrine 
(Shadnia et al, 2008). Most of the analgesic effect of tramadol may be secondary to 
non-opioid properties, via the central monoaminergic pathways. The most common 
route of administration of tramadol is oral. Opioid dependency, overdose, and related 
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complications are common in Iran in various age groups and gender (Koushesh et 
al,2009). In recent years, tramadol overdose has become one of the most common 
causes of poisoning admissions to emergency departments in this country (Talaie et 
al,2009). An increased rate of seizure due to tramadol poisoning has also been observed 
It is reported that 15% to 35% of patients with tramadol overdose experience seizure       
(Kroenke et al.2009). Research indicates that in high concern tractions tramadol exerts 
an inhibitory effect on gamma aminobutyric acid (GABA) receptors. In addition, 
GABA receptor inhibition induced by tramadol can be secondary to its opioid receptor 
agonist activity (Rehni et al, 2008), and continuing this agonist activity on opioid 
receptor has been proven to precipitate seizure due to inhibition of GABA pathways In 
addition to overdose, seizures have been reported  in patients receiving tramadol at  
recommended doses (Kahn et al,1997).                                                                                
Tramadol may also increase the seizure risk in patients receiving other medications such 
as tricyclic antidepressants, phenothiazine's, and selective serotonin reuptake inhibitors. 
While tramadol-related seizures can be controlled by diazepam, they are not responsive 
to naloxone, and tramadol-induced seizures can be precipitated by administration of 
naloxone, at high tramadol doses (Raffa &Stone,2008). The analgesic effect of tramadol 
is dose dependent. The relation between serum concentrations and analgesia varies 
between individuals. It is estimated that serum concentrations of 100 to 300 ng/mL are 
needed for analgesia  (Shadnia et al b, 2008). In medical literature, no study in regard to 
blood concentrations of tramadol-induced seizures is available.                                        
                                        
2.9.2Description of Tramadol 
Tramadol is an analgesic medication that is a synthetic analogue of codeine. In 
comparison with other opiates, tramadol is renowned for having less abuse potential and 
less respiratory depression. In terms of specific neurotransmitter effects, at the central 
level, tramadol is a mu-opioid receptor agonist. The affinity of tramadol for mu-opioid 
receptors (analgesic effect) is 10-fold less than codeine. However, the active metabolite 
of tramadol, o-desmethyltramadol, has a far greater affinity (up to 200-fold) than the 
parent compound. In addition to its central effects on mu receptors, at the peripheral 
level, tramadol inhibits serotonin and norepinephrine reuptake. These latter effects are 
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likely to be an important element in analgesia, but may also account for some of the 
adverse properties of the drug(Gold S, 2008). 
 
2.9.3Tramadol poisonings main features and toxicity 
Originally it was claimed that tramadol is rather safe and has low potential for abuse. 
However, contradicting evidence has emerged in later stages. Food and Drug 
Administration has issued safety alert on this drug, including special cautions for 
patients who are simultaneously taking tranquilizers or antidepressants as well as 
individuals who consume alcohol excessively, or for those who suffer from emotional 
disturbances or depression. Potential misuse abuse and diversion were also stressed. 
Consistently, it has been recently suggested to place tramadol into the Schedule of the 
Controlled   Substances Act Complications in tramadol overdose are  disproportionately 
higher(Fass J, 2010).                                                                                                           
Much of the toxicity in tramadol overdose appears to be attributable to the monoamine 
uptake inhibition rather than its opioid effects(Spiller HA et al ,1997). Frequency of 
theamadol induced complications is on the rise. Prescription on the Internet, initial 
marketing on safety, low potential for abuse and diversion as well as 
dextropropoxyphene withdrawal in hospital settings have been contributive on 
this(Bäckstrometal,2010).                                                                                                     
Reported tramadol overdoses are dominantly   intentional acute ingestions. The majority 
of cases become symptomatic within the first 4 hours of ingestion.                                    
                                  
2.9.4Adverse effects 
The most commonly reported adverse drug reactions are nausea, vomiting, sweating, 
itching and constipation. Drowsiness is reported, although it is less of an issue than for 
non-synthetic opioids. Patients prescribed tramadol for general pain relief with or 
without other agents have reported withdrawal symptoms including uncontrollable 
nervous tremors, muscle contracture, and thrashing in bed similar to restless leg 
syndrome if weaning off the medication happens too quickly. Anxiety, buzzing, 
'electrical shock' and other sensations may also be present, similar to those noted in 
Effexor withdrawal. Respiratory depression, a common side-effect of most opioids, is 
not clinically significant in normal doses. By itself, it can decrease the seizure threshold. 
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When combined with SSRIs, tricyclic antidepressants, or in patients with epilepsy, the 
seizure threshold is further decreased. Seizures have been reported in humans receiving 
excessive single oral doses (700 mg) or large intravenous doses (300 mg). However, 
there have been several rare cases of people having grand-mal seizures at doses as low 
as 100–400 mg orally( Pseudome,2009). An Australian study found that of 97 
confirmed new-onset seizures, eight were associated with tramadol, and that in the 
authors First Seizure Clinic, tramadol is the most frequently suspected cause of 
provoked seizures (Labate, 2005). There appears to be growing evidence that tramadol 
use may have serious risks in some individuals and it is contra-indicated in patients with 
uncontrolled epilepsy (BNF 59). Seizures caused by tramadol are most often tonic-
clonic seizures, more commonly known in the past as grand mal seizures. Also when 
taken with SSRIs, there is an increased risk of serotonin toxicity, which can be fatal. 
Fewer than 1% of users have a presumed incident seizure claim after their first tramadol 
prescription. Risk of seizure claim increases two- to six-fold among users adjusted for 
selected comorbidities and concomitant drugs. Risk of seizure is highest among those 
aged 25–54 years, those with more than four tramadol prescriptions, and those with a 
history of alcohol abuse, stroke, or head injury(Gardner,2000) . Dosages of warfarin 
may need to be reduced for anticoagulated patients to avoid bleeding complications. 
Constipation can be severe especially in the elderly requiring manual evacuation of the 
bowel. Furthermore, there are suggestions that chronic opioid administration may 
induce a state of immune tolerance, although tramadol, in contrast to typical opioids 
may enhance immune function. Some have also stressed the negative effects of opioids 
on cognitive Seizure functioning and personality.                                                             
                                                              
2.9.5 Physical dependence and withdrawal 
Tramadol is associated with the development of physical dependence and a severe 
withdrawal syndrome(Barsotti et al .,2003) . Tramadol causes typical opiate-like 
withdrawal symptoms as well as atypical withdrawal symptoms including seizures. The 
atypical withdrawal symptoms are probably related to tramadol's effect on serotonin and 
norepinephrine re-uptake. Symptoms may include those of SSRI discontinuation 
syndrome, such as anxiety, depression, anguish, severe mood swings, aggressiveness, 
brain, electric-shock-like sensations throughout the body, paresthesias, sweating, 
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palpitations, restless legs syndrome, sneezing, insomnia, vivid dreams or nightmares, 
nonsense and weird thoughts, micropsia and/or macropsia, tremors, and headache 
among others. In most cases, tramadol withdrawal will set in 12–20 hours after the last 
dose, but this can vary. Tramadol withdrawal lasts longer than that of other opioids; 
seven days or more of acute withdrawal symptoms can occur as opposed to typically 
three or four days for other codeine analogues. It is recommended that patients 
physically dependent on pain killers take their medication regularly to prevent onset of 
withdrawal symptoms and this is particularly relevant to tramadol because of its SSRI 
and SNRI properties, and, when the time comes to discontinue their tramadol, to do so 
gradually over a period of time that will vary according to the individual patient and 
dose and length of time on the drug.( Choong et al, 2008). 
 
2.9.6 Psychological dependence and recreational use 
Some controversy regarding the abuse potential of tramadol exists. Grünenthal has 
promoted it as an opioid with a lower risk of opioid dependence than that of traditional 
opioids, claiming little evidence of such dependence in clinical trials which is true; 
Grünenthal never claimed it to be non-addictive. They offer the theory that, since the 
M1 metabolite is the principal agonist at μ-opioid receptors, the delayed agonist activity 
reduces abuse liability. The norepinephrine reuptake inhibitor effects may also play a 
role in reducing dependence. 
It is apparent in community practice that dependence to this agent may occur after as 
little as three months of use at the maximum dose generally depicted at 400 mg per day. 
However, this dependence liability is considered relatively low by health authorities, 
such that tramadol is classified as a Schedule 4 Prescription Only Medicine in Australia, 
and been rescheduled in Sweden rather than as a Schedule 8 Controlled Drug like 
opioids. Similarly, tramadol is not currently scheduled by the U.S. DEA, unlike opioid 
analgesics. It is, however, scheduled in certain states. Nevertheless, the prescribing 
information for Ultram warns that tramadol may induce psychological and physical 
dependence of the morphine-type. Using tramadol as recreational drug may be preferred 
also because at this time, tramadol is the only opioid, that cannot be detected by the 
standard urinal drug-tests, due to its atypical binding to μ-opioid receptors. Dependence 
on tramadol has been reported to be a major social problem in the Gaza Strip. The 
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Hamas government has attempted to cut off supplies of the drug, and in April 2010 
burnt 2 million tablets which had been intercepted while being smuggled into the 
territory. 
Because of the possibility of convulsions at high doses for some users, recreational use 
can be very dangerous(Jovanović et al.,2006). Tramadol can, however, via agonist of μ 
opioid receptors, produce effects similar to those of other opioids (codeine and other 
weak opioids), although not nearly as intense due to tramadol's much lower affinity for 
this receptor. Tramadol can cause a higher incidence of nausea, dizziness, loss of 
appetite compared with opiates which could deter abuse to some extent(Rodriguez et 
al,2007) . Tramadol can help alleviate withdrawal symptoms from opiates, and it is 
much easier to control the quantity of its usage than street drugs(Adams et al ,2006)  .  
It may also have large effect on sleeping patterns and high doses may cause insomnia. 
Especially for those on methadone, both for maintenance and recreation. Though there 
is no scientific proof tramadol lessens effects or is a mixed agonist-antagonist, some 
people get the impression it is, while someone else might benefit being prescribed both 
for pain and breakthrough pain(Vorsanger et al.,2008) . 
  
2.9.7 Tramadol and Serotonin syndrome 
Serotonin syndrome (SS) has been reported with tramadol overdose-induced SS remains 
unknown; however, it probably does not exceed 5 % in hospital settings(Tashakori A,& 
Afshari,2010). SS may occur during single tramadol use, but it appears to be more 
common following either excessive use or overdose or with the co-administration of 
other medications, particularly antidepressants. No association was found between the 
frequency of SS and the alleged dose of tramadol overdose. Tramadol could have a 
synergistic effect on other drug induced SS. It may occur with tramadol monotherapy, 
but SS has been documented in combinations of tramadol and the following 
medications, (Mahlberg et al,2004) citalopram, fluoxetine, fluvoxamine, moclobemide-
clomipramine, mirtazapine, paroxetine, sertraline and venlafaxine. Interestingly, we are 
convinced that true rate of tramadol-induced SS might be even higher than currently 
reported, if agitation, tachycardia, confusion, and hypertension were considered as 




SS may develop via.(Sun-Edelstein et al.,2008): 
(i) excessive serotonergic agonism of serotonin receptors in the central and peripheral 
nervous systems . 
(ii) as a result of increased serotonin synthesis. 
 (iii) decreased serotonin metabolism. 
(iv) increased serotonin release. 
 (v) inhibition of serotonin reuptake (e.g. SSRIs). 
(vi) direct agonism of serotonin receptors. 
 Tramadol, in addition to affecting μ-opioid receptors, stimulates pre-synaptic release of 
serotonin and inhibits serotonin reuptake(Kitson R, Carr .,2005). Otherwise, SSRIs can 
inhibit the CYP2D6 isoenzyme metabolising tramadol, resulting in therapeutic overdose 
of tramadol and, in susceptible individuals, idiosyncratic induction of SS.overdoses. 
 
2.9.8 Biological features   
Tramadol overdose may induce a rise of creatinine phospho kinase (CPK). Although 
CPK rise could be independent from seizure, in cases with seizure, CPK rise is more  
dramatic and may be associated to acute renal failure(Boyd ,2005).                                
Increase in white blood cell count has been reported(Tashakori & Afshari, 2010). 
Bleeding risks due to tramadol interaction with oral anticoagulants has also been 
stated(Hersh EVet al.,2007). 
 
2.9.9 Availability of tramadol  
Tramadol is classified as a central nervous system drug usually marketed as the 
hydrochloride salt (tramadol hydrochloride); the tartrate is seen on rare occasions, and 
rarely (in the US at least) tramadol is available for both injection (intravenous and/or 
intramuscular) and oral administration. The most well-known dosing unit is the 50 mg 
generic tablet made by several manufacturers. It is also commonly available in 
conjunction with APAP (paracetamol, acetaminophen) as Ultracet, in the form of a 
smaller dose of 37.5 mg tramadol and 325 mg of APAP. The solutions suitable for 
injection are used in patient-controlled analgesia pumps under some circumstances, 




Tramadol comes in many forms, including: 
 capsules (regular and extended release). 
 tablets (regular, extended release, chewable, low-residue and/or uncoated tablets 
that can be taken by the sublingual and buccal routes). 
 suppositories. 
 effervescent tablets and powders. 
 ampules of sterile solution for SC, IM, and IV injection. 
 preservative-free solutions for injection by the various spinal routes (epidural, 
intrathecal, caudal, and others). 
 powders for compounding. 
 liquids both with and without alcohol for oral and sub-lingual administration, 
available in regular phials and bottles, dropper bottles, bottles with a pump similar 
to those used with liquid soap and phials with droppers built into the cap. 





















2.10 Previous studies  
Study of (Emamhadi M et al .,2012) 
Electrocardiographic manifestations of tramadol toxicity with special reference to 
their ability for prediction of seizures. 
The aims of this study are to determine the electrocardiographic (ECG) manifestations 
of the symptomatic patients with isolated tramadol toxicity and to predict seizures based 
on ECG parameters. 
Medical charts of a total of 479 patients with isolated tramadol toxicity were 
retrospectively evaluated. Their clinical manifestations were recorded, and their ECG 
parameters including rate, PR interval, QRS duration, corrected Q  T interval, terminal 
40-millisecond frontal plane QRS axis, and the height of R wave and R/S ratio in the 
lead aVR were measured. The data were analyzed using Kolmogorov-Smirnov test, 
Mann-Whitney U test, Pearson χ(2), Pearson correlation coefficient (r), and the Student 
t test. 
Electrocardiographic heart rate more than 100 beats per minute in 30.6%, QRS 120 
milliseconds or more in 7.5%, corrected QT interval more than 440 milliseconds in 
24.6%, height of R wave more than 1 mm in lead aVR in 22.1%, R/S ratio more than 0 
in lead aVR in 23.5%, terminal 40-millisecond frontal plane QRS axis greater than 120° 
in 31.7%, and complete or incomplete right bundle-branch block in 4.6% of the patients 
were detected. There were no statistically significant differences between the patients 
who had not convulsed and those who had convulsed after admission regarding age, 
sex, vital signs, and ECG findings at presentation (all P values were >.05). 
Tramadol toxicity shows ECG changes consistent with sodium channel blockade and 
potassium channel blockage effects. The risk of development of seizures cannot be 
predicted based on the changes of ECG parameters at presentation. 
Study of (Kaynar M et al .,2012) 
 On-demand tramadol hydrochloride use in premature ejaculation treatment. 
The purpose of this study is To determine the efficacy of tramadol in premature 
ejaculation (PE) treatment compared with placebo. 
A single-blind, placebo-controlled, crossover study was conducted with 60 lifelong 
(primary) patients with PE. The patients were randomized into 2 groups, each consisting 
of 30 patients, who took tramadol or placebo on demand. PE was defined as an 
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intravaginal ejaculation latency time of ≤60 seconds in 90% of intercourse episodes. 
The efficacy of the drugs was assessed using the intravaginal ejaculation latency time, 
ability of ejaculation control, and sexual satisfaction scores after an 8-week treatment 
period. 
All participants completed the study voluntarily. Two groups were similar in terms of 
the patient demographics. Increases in the intravaginal ejaculation latency time, ability 
of ejaculation control, and sexual satisfaction score between the placebo and tramadol 
groups were compared with the baseline values in both groups. At the end of study 
period, the tramadol group had significantly (P<.001) greater values for all 3 parameters 
compared with those in the placebo group. 
On-demand use of low-dose tramadol is effective for lifelong PE. 
Study of (Xiong  GG et al .,2011 )  
Safety and efficacy of tramadol hydrochloride with behavioral modification in the 
treatment of premature ejaculation. 
To evaluate the efficacy and safety of tramadol hydrochloride with behavioral 
modification in delaying ejaculation in patients with premature ejaculation. 
Seventy-two potent men with premature ejaculation were equally and randomly 
assigned to a treatment group and control group, the former received 50 mg tramadol 
hydrochloride with behavioral modification approximately 2 hours before planned 
sexual activity, while the latter underwent behavioral therapy only, both treated for 8 
weeks. Intravaginal ejaculatory latency time (IELT), intercourse satisfaction of the 
partners, total therapeutic effectiveness, adverse reactions, and hepatic and renal 
function of the patients were recorded and compared before and after the treatment. 
Both the treatment and the control groups showed significant differences from 
pretreatment in the mean IELT and intercourse satisfaction domain values (P < 0.01). 
The total rate of effectiveness was 72.2% in the treatment group and 47.2% in the 
control. The former exhibited even more significant improvement than the latter in the 
mean IELT, intercourse satisfaction domain values and total rate of effectiveness (P < 
0.05). Adverse reactions occurred in 10 cases (27.8%), and no statistically significant 
differences were found in hepatic and renal function before and after treatment (P > 
0.05). Tramadol hydrochloride with behavioral modification showed positive effects in 
prolonging IELT and improving partners' intercourse satisfaction. 
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Study of (Bar-Or D et al.,2011) 
A Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate 
the Efficacy and Safety of Two Doses of the Tramadol Orally Disintegrating Tablet 
for the Treatment of Premature Ejaculation Within Less Than 2 Minutes. 
To assess the safety of tramadol orally disintegrating tablet (ODT) (Zertane) and its 
efficacy in prolonging intravaginal ejaculation latency time (IELT) and improving 
Premature Ejaculation Profile (PEP) scores. 
He  conducted an integrated analysis of two identical 12-wk randomized double-blind, 
placebo-controlled phase 3 trials across 62 sites in Europe. Healthy men 18-65 yr of age 
with a history of lifelong PE according to the Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition. 
Subjects were randomized to receive 1:1:1 placebo (n=200), 62mg tramadol ODT 
(n=206), or 89mg tramadol ODT (n=198). 
We measured overall change and fold increase in median IELT and the mean change in 
all four measures of the PEP. Differences across treatment groups were analyzed using 
Wilcoxon rank-sum tests, analysis of variance, and chi-square analyses. 
Tramadol ODT resulted in significant increases in median IELT compared with 
placebo; increases were 0.6min (1.6 fold), 1.2min (2.4 fold), and 1.5min (2.5 fold) for 
placebo, 62mg tramadol ODT, and 89mg tramadol ODT, respectively (p<0.001 for all 
comparisons). Men saw significantly greater improvement in all four measures of the 
PEP in both doses compared with placebo (p<0.05 for all comparisons). Tramadol ODT 
was well tolerated; study discontinuation occurred in 0%, 1.0%, and 1.6% of subjects in 
placebo, 62mg, and 89mg tramadol ODT groups, respectively. Limitations include 
study inclusion for men with IELT up to 120s. 
On-demand 62mg tramadol ODT is an effective treatment for PE in a low and safe 
therapeutic dose and provides anew option for managing mild to severe PE. 
Study of (Yarkan et al.,2011) 
Epileptic seizure following IV tramadol in a patient with mental retardation and 
cerebellar ataxia. 
To present a case of an epileptic seizure related to intravenous (IV) tramadol for pain 
control following a total abdominal hysterectomy operation on a patient with mental 
retardation and cerebellar ataxia. 
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A 42-year-old female with mental retardation and cerebellar ataxia presented with an 
epileptic seizure after administration of IV tramadol for postoperative pain. Magnetic 
resonance imaging scans were normal, but laboratory tests showed hypocalcemia. Next, 
calcium replacement was administered. Postoperative pain treatment with tramadol was 
discontinued because tramadol was felt to be a possible cause of the seizure observed in 
this patient. In order to treat the epileptic seizure, IV phenytoin sodium infusion was 
started. On the second postoperative day, calcium levels were found to be normal, and 
the IV antiepileptic medication was changed to an oral form. The patient had no 
subsequent seizures during the clinical follow-up. She was discharged on the fourth 
postoperative day without any other complications. 
Even in recommended doses ,IV tramadol may cause epileptic seizures on predisposed 
patients. 
Study of(Lanier Rk et al .,2010) 
Physical dependence potential of daily tramadol dosing in humans. 
The current study assessed the level of physical dependence and opioid blockade 
efficacy produced by daily maintenance on oral tramadol. 
Nine residential opioid-dependent adults were maintained on two doses of daily oral 
tramadol (200 and 800 mg) for approximately 4-week intervals in a randomized, 
double-blind, crossover design. The acute effects of intramuscular placebo, naloxone 
(0.25, 0.5, and 1.0 mg), and hydromorphone (1.5, 3.0, and 6.0 mg) were tested under 
double-blind, randomized conditions. Outcomes included observer- and subject-rated 
measures and physiologic indices. 
Challenge doses of naloxone resulted in significantly higher mean peak withdrawal 
scores compared to placebo. Withdrawal intensity from naloxone was generally greater 
during 800 versus 200 mg/day tramadol maintenance. Mean peak ratings of agonist 
effects were elevated at higher hydromorphone challenge doses, but did not differ 
significantly between tramadol doses. Physiologic measures were generally affected by 
challenge conditions in a dose-dependent manner, with few differences between 
tramadol maintenance dose conditions. 
Chronic tramadol administration produces dose-related opioid physical dependence 
without producing dose-related attenuation of agonist challenge effects. Tramadol, may 
be a useful treatment for patients with low levels of opioid dependence or as a treatment 
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for withdrawal during opioid detoxification, but does not appear to be effective as 
maintenance medication due to a lack of opioid cross tolerance .                                       
Study of (Tashakori & Afshari,2010) 
Tramadol overdose as a cause of serotonin syndrome: a case series. 
Tramadol overdose impairs consciousness and may induce ECG changes and 
convulsions. These effects may be opioid and/or serotonin related. This study describes 
clinical manifestations, electrophysiological and hemodynamic findings, and the 
frequency of potential serotonin syndrome in tramadol overdose in a case series. It also 
focuses on potential factors by which convulsions could be predicted. 
This is a prospective observational case series. All cases admitted with suspected 
tramadol overdose from September 1, 2006 to August 31, 2007 were included. 
Tramadol overdose accounted for 1.2% of all poisonings (n = 158), of which 65% were 
tramadol only. It was predominantly male (63%). Mean age was 22.6 (7.4) years. 
Among these cases, 24 (15%) experienced seizure and in 10 (6%) cases creatine 
phosphokinase increased. Death occurred in one patient. Seizure occurred more 
frequently in patients with tramadol use only (odds ratio 3.0, 95% confidence interval 
1.1, 8.4) and mydriasis (odds ratio 8.9, 95% confidence interval 1.9, 42.4) on admission. 
Eight cases were treated for potential serotonin syndrome. Concurrent intoxication with 
central nervous system depressants, age, alleged dose, consciousness level, respiratory 
rate, history of drug abuse, and naloxone administration was not associated with the 
occurrence of seizures. 
Study of (Rehni et al .,2010) 
 Tramadol-induced seizurogenic effect: a possible role of opioid-dependent 
histamine H1 receptor activation-linked mechanism. 
The present study has been designed to investigate the role of opioid receptors, mast 
cells, and histamine receptors (H(1) subtype) in the seizurogenic effect of tramadol on 
pentylenetetrazole-treated mice. A single injection of pentylenetetrazole (80 mg kg(-1)) 
was used to elicit seizure activity in mice. Seizures were assessed in terms of the time 
latency of the onset of Straub-like tail, onset of jerky movements of whole body, 
convulsions, and death. Tramadol administration (50 mg kg (-1)) caused a marked 
increase in seizurogenic activity of pentylenetetrazole as measured in terms of a 
significant decrease in the time latency of the onset of Straub-like tail, jerky movements 
of whole body, convulsions, and death. Moreover, prior administration of naloxone (2 
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mg kg(-1)), fexofenadine (100 mg kg(-1)), cetrizine, sodium cromoglycate, and 
ketotifen (10 mg kg(-1)), respectively, attenuated the seizurogenic activity that tramadol 
exerted on pentylenetetrazole-treated mice. Therefore, it may be suggested that tramadol 
exerts a seizurogenic effect on mice via an H(1) receptor activation-linked pathway 
possibly through an opioid receptor-dependent release of histamine from the mast cells . 
Study of (Afshari R& Ghooshkhanehee H, 2009) 
Tramadol overdose induced seizure, dramatic rise of CPK and acute renal failure. 
Tramadol, an analgesic with a low affinity to opioid receptors, inhibits the reuptake of 
norepinephrin and serotonin. It is also abused by opioid addicts. Tramadol overdose can 
induce CNS and respiratory depression, tachycardia, and seizures. In this report, a 19 
years male was admitted due to suicidal attempt of ingestion of 4000 mg of Tramadol. 
He experienced frequent seizures, confusion, myosis, and dramatic rise of CPK, LDH 
and Creatinine. Improvement was had in the following days by administering fluids, 
NaHCO3 and chlordiasopoxide and routine management. He was discharged with no 
further sequelae. 
Study of (Talaie H et al .,2009 ) 
Dose-independent occurrence of seizure with tramadol. 
In this study the researcher  assessed the incidence of seizure, as it is one of the most 
important adverse effects. 
In a cross-sectional study, 215 cases of tramadol users or abusers who were admitted to 
Loghman-Hakim Hospital Poisoning Center (LHHPC) in Tehran during a 5-month 
period, from April 2007 to September 2007, were assessed to evaluate the occurrence of 
seizure. Patients with positive history of co-ingestion of other drugs, addiction, 
convulsive disorders, renal diseases, or head trauma with abnormal 
electroencephalography (EEG) or computerized tomography (CT) scan of the brain 
were excluded, thus 132 patients were included in the study. For patients who had 
seizure, CT scan of the brain and EEG were performed, and frequency and type of 
seizure were identified. Mean tramadol dose was compared between patients with and 
without seizure. 
Among the patients, 97 (73.5%) were male. Seizure occurred in 61 patients (46.2%) 
within 24 hours after tramadol ingestion. The majority of patients who had seizure were 
male (male, 83.6% vs. female, 16.4%). Mean tramadol dose was lower among females 
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than males (males, 2413 mg vs. females, 1706 mg), but the difference was not 
statistically significant. Of 35 patients with documented seizure type, all showed 
generalized tonic-clonic seizure and 12 patients had abnormal EEG (35.3%). No 
statistically significant difference was observed in mean tramadol intake between 
patients with or without seizure. Analysis of patients with seizure, according to 
tramadol intake, indicated that most patients used tramadol in the dose range of 500-
1000 mg followed in occurrence by 1500-2000 mg, then 100-500 mg, 2500-3000 mg, 
and 3500-4000 mg. 
Mean tramadol intake does not differ between patients with and without seizure, and the 
most common dose range in those with seizure is 500-1000 mg. We thus conclude that 
the incidence of seizure with tramadol is not dose dependent . 
Study of (Sansone RA et al., 2009)  
Tramadol: seizures, serotonin syndrome, and coadministered antidepressants. 
This ongoing study is dedicated to the challenging clinical interface between psychiatry 
and primary care-two fields that are inexorably linked. Tramadol (Ultram) is a 
commonly prescribed analgesic because of its relatively lower risk of addiction and 
better safety profile in comparison with other opiates. However, two significant adverse 
reactions are known to potentially occur with tramadol-seizures and serotonin 
syndrome. These two adverse reactions may develop during tramadol monotherapy, but 
appear much more likely to emerge during misuse/overdose as well as with the 
coadministration of other drugs, particularly antidepressants. In this article, we review 
the data relating to tramadol, seizures, and serotonin syndrome. This pharmacologic 
intersection is of clear relevance to both psychiatrists and primary care clinicians. 
Study of (Tjäderborn M et al .,2009 ). 
 Tramadol dependence: a survey of spontaneously reported cases in Sweden. 
The aim of this study was to investigate occurrence of tramadol dependence and 
associated risk factors using spontaneously reported adverse drug reactions. 
The Swedish database for spontaneously reported adverse drug reactions, Swedish Drug 
Information System (SweDIS), was searched for reports on tramadol dependence from 
1 January 1995 until 31 December 2006. Selection was conducted based on the DSM-
IV definition of dependence. Available information was scrutinized and registered and 
then presented descriptively. 
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A total of 104 reports of tramadol dependence were identified, of which 60 (58%) 
concerned women. The median age (range) was 45 (15-84) years. Information on a 
history of substance abuse was present in 31 patients (30%) and 41 patients (39%) had a 
documented past or current use of a drug of abuse. Prescribed doses of tramadol ranged 
between 50-800 mg/day, and ingested doses between 50-4000 mg/day. Time of onset 
ranged from some weeks up to 4 years. In 72 (69%) cases the reaction was classified as 
serious, mainly due to hospitalizations for detoxification or discontinuation of tramadol. 
There is an occurrence of tramadol dependence in association with analgesic treatment 
within the recommended dose range. In susceptible patients a severe and serious 
dependence syndrome may develop. A history of abuse or use of a drug of abuse seems 
to be an important risk factor. 
Study of (Pollice R et al.,2008) 
Severe tramadol addiction in a 61 year-old woman without a history of substance 
abuse. 
This study describe the first case of Tramadol addiction and withdrawal in an elderly 
female patient in apparently good physical health. We report successful treatment with 
mirtazapine and clonidine. We believe that patients must be advised to take Tramadol 
regularly and to stop gradually especially after long treatment periods; moreover 
physicians must consider the potential physical dependence when they prescribe 
Tramadol for pain. Hence, we are observing some patients who continue to take 
Tramadol in order to achieve a feeling of well-being, even though their pain is 
controlled after disease regression. Finally, the establishing of an evidence-based 
tramadol detoxification protocol would be highly desirable.                                             
Study of (Shadnia S et al .,2008 ) 
Tramadol intoxication: a review of 114 cases. 
Tramadol as a centrally acting analgesic is extensively used in the management of 
moderate to severe pain. It slightly affects opioid receptors and inhibits the reuptake of 
norepinephrin and serotonin in the CNS. There are reports about toxicity and abuse of 
tramadol. The objective of the present study was to evaluate epidemiology of intentional 
tramadol intoxications. All poisoning cases that admitted to Loghman-Hakim Hospital 
Poison Center from April to May 2007 were studied. A total of 114 cases (82 men and 
32 women) of intentional tramadol intoxications with the median age of 23.66 +/- 6.87 
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years (range 16-54 years) were identified. Other illicit drugs were found to be used in 
combination with tramadol in some of the cases, which among them benzodiazepines 
were the most common. Tramadol overdose has been one of the most frequent causes of 
drug poisoning in the country in the recent years, especially in male young adults with 
history of substance abuse and mental disorders. Nausea, vomiting, Central Nervous 
System (CNS) depression, tachycardia, and seizure are the most common findings in 
this kind of poisoning. Cardiopulmonary arrest was found as the cause of death in cases 
who had ingested more than 5000 mg tramadol. 
Study of (Salem EA et al.,2008) 
Tramadol HCL has promise in on-demand use to treat premature ejaculation. 
Premature ejaculation (PE) is a worldwide problem without an approved treatment. 
Selective serotonin reuptake inhibitors (SSRIs) are widely used "off label" as 
pharmacotherapeutic agents in the treatment of PE. 
This study investigates Tramadol efficacy for on-demand treatment of PE. 
Intravaginal ejaculation latency time (IELT) was used as an objective tool to assess the 
efficacy of the investigated treatments. 
Single-blind, placebo-controlled, crossover, stopwatch monitored two-period study was 
conducted, on 60 patients with lifelong PE. PE was defined as IELT of <2 minutes in 
80% of intercourse episodes. A total of 25 mg of Tramadol hydrochloride was given to 
one group (30) prior to intercourse and placebo was supplied for the other group (30) 
for 8 weeks. Drugs were taken 1-2 hours before sexual activity and sexual intercourse 
was required at least once per week. After the initial treatment period, the two groups 
took the alternate medication for another 2 months. The two 8-week treatment periods 
were separated by 1 week washout period. IELT was timed by a stopwatch at each 
intercourse and was reported by patients or partners. 
The baseline (mean +/- SD) IELT for patients before treatment was 1.17 +/- 0.39 
minutes. At the end of the treatment period utilizing the active drug, the mean IELT was 
increased significantly in patients on Tramadol treatment to 7.37 +/- 2.53 minutes. The 
same patients on placebo medication had mean IELT of only 2.01 +/- 0.71 minutes. 





Study of (Jovanović-Cupić V et al .,2006) 
Seizures associated with intoxication and abuse of tramadol. 
The purpose of this study is to assess the frequency of seizures and patient 
characteristics associated with tramadol intoxication and abuse in young addicts. 
Patients with history of tramadol abuse and intoxication were prospectively studied 
during a 3-year period. The characterstics of patients with seizures and those without 
seizures were compared. 
Fifty-seven patients (mean age 22.3 years [range 16-43 years], 47 males) were included. 
Tonic/clonic seizures occurred in 31 (54.4%) patients, (26 males and 5 females): single 
in 14 (45%), multiple in 17 (55%) patients after a tramadol dose ranging from 250-2500 
mg. Seizures occurred within 24 h after tramadol intoxication in 26 (84%) patients, and 
later in 5 (16%) patients. Compared to addicts without seizures, the abusers with 
seizures were younger (p < 0.05). Both epileptiform and nonepileptiform 
electroencephalographic patterns were more common in patients with seizures than in 
patients without seizures, but the differences did not reach statistical significance. 
The neurotoxicity of tramadol commonly manifests as generalized tonic-clonic seizures 
occurring most frequently within 24 h after tramadol intake. Seizures were more 
common in younger abusers with a longer duration of exposure to tramadol and with the 
combined use of tramadol with alcohol. 
 
 
Study of (Alafifi et al .,2005) 
Drug Misuse Among University Students In the Gaza Strip 
This study was aimed to assess the prevalence of drug misuse among university students 
in Gaza strip , it consist of two phase. The first phase of the project entailed surveying 
the high schools in the Gaza Strip and was carried out in 2002-2003. The second phase 
was carried out in 2004 in the universities of the Gaza Strip.   
A sample of 491 students (248 males and 243 females) were randomly selected from 
five universities in the Gaza Strip in the second and fourth year, during the second 
phase of the project. The survey revealed a prevalence of use of a drug one or more 
times: Marijuana (4.6% of male students and 1.2% of female students); consumption of 
beer and other alcoholic products (7.1% among males, 2.6% among females); tried 
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powder (heroin or cocaine) (2.8% of males and 1.6% of females); use of CNS stimulant 
tablets (5.4% of males, 1.3% of females); use of inhalants (9.1% of males and 1.6% of 
females); and use of other narcotics including ecstasy and locally made materials (1.6% 
of males and 0.8% of females) . 
Study of (Näslund S& Dahlqvist R,2003). 
Treatment with tramadol can give rise to dependence and abuse. 
Tramadol is a centrally acting opioid analgesic which is increasingly used in Sweden. 
Dependence, abuse and withdrawal has been reported in patients treated with tramadol. 
The incidence of these adverse effects is considered to be low. Patients with a history of 
substance abuse might be at higher risk than others to develop dependence. The number 
of forged tramadol prescriptions uncovered in Swedish pharmacies was relatively low in 
2001, compared to those of prophoxyphene and codien ,but increasing .                            
Study of (Senay EC et al., 2003) . 
Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and 
atypical withdrawal symptoms occur. 
In 1994, the Drug Abuse Advisory Committee (DAAC) of the Food and Drug 
Administration (FDA) concluded that Ultram (tramadol hydrochloride) could be 
marketed as an analgesic drug without scheduling under the Controlled Substances Act 
based upon extensive pre-clinical, clinical and European epidemiological data. 
However, to guard against unexpectedly high levels of abuse in the United States, the 
DAAC recommended that an independent steering committee (ISC) be appointed to 
proactively monitor abuse/dependence. In the event that high rates of abuse were found, 
this ISC was given the authority to immediately recommend to the FDA that Ultram be 
scheduled. In the course of the surveillance project, the ISC received reports of 
withdrawal following abrupt discontinuation of Ultram and in some instances, following 
dose reductions. In most cases, the withdrawal symptoms consisted of classical opioid 
withdrawal, but in some cases were accompanied by withdrawal symptoms not 
normally observed in opiate withdrawal, such as hallucinations, paranoia, extreme 
anxiety, panic attacks, confusion and unusual sensory experiences such as numbness 
and tingling in one or more extremities. Withdrawal symptoms of either type were one 
of the more prevalent adverse events associated with chronic Ultram use, comprising 
nearly 40% of all adverse events reported with Ultram. Most of these consisted of 
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typical opiate withdrawal symptoms, but 1 in 8 cases presented as atypical. These 
results indicate that physicians and other healthcare professionals need to be aware of 
the potential of Ultram to induce withdrawal of the classical opioid type, and that 
atypical withdrawal may also occur.                                                                                     
Study of (Liu ZM,1999). 
Drug dependence and abuse potential of tramadol. 
This study aimed to assess the drug dependence and abuse liability of tramadol. 
Subjects of opiate addicts with history of tramadol abuse were 219. Physical 
dependence of tramadol was assessed using opiate withdrawal scale (OWS), psychic 
dependence was assessed by association test of Addiction Research Center Inventory-
Chinese Version (ARCI-CV); the degrees of craving experienced for tramadol was self-
reported on visual analogue scale (VAS). 
The scores of OWS of tramadol were 0.05-1.07; 3 scores on scales in particular being 
used the identify euphoric effects--MBG, sedative effects--PCAG, and psychotomimetic 
effects--LSD of ARCI were 7.3, 6.1, and 3.4, respectively (F = 38.1, P < 0.01); 57.1% 
of tramadol abuse subjects had craving for tramadol (chi 2 = 75.86, P < 0.01). 
Tramadol produced high abuse potential among opiate addicts. 
Study of (Tobias JD,1997) 
Seizure after overdose of tramadol. 
Tramadol (Ultram) is a new analgesic agent with a dual mechanism of action that 
includes weak agonistic effects at the mu-opioid receptor as well as inhibition of 
neurotransmitter (serotonin, norepinephrine) re-uptake. Although it has proven to be a 
safe and effective agent for the control of pain, adverse effects can occur with its use. 
He report the occurrence of seizure activity after the inadvertent administration of 4 
mg/kg of tramadol to a child. Previous reports of seizure activity after tramadol 
administration.    
2.10.1 Comment about previous studies  
According to the literature review that mentioned by the researcher there are a few of 
studies about the tramadol abuse but the mentioned studies  clarified the following : 
1-The relationship between tramadol and its effect on premature ejaculation. 
2- The relation between the use of tramadol and the potential of dependence . 




4- The effect of tramadol as anti-depressant . 
5- The effect of tramadol on changing of ECG . 
6- The toxicity of tramadol abuse . 
7- Convulsions that caused by abuse of tramadol . 
8- Abusing  of tramadol and serotonin syndrome . 
The Kaynar M et al (2012) confirm that using of tramadol with low dose can help in 
treatment of premature ejaculation , they use the comparison between two groups of 
people complain of premature ejaculation one group was giving placebo and the another 
group was giving low dose of tramadol , the result observed that the group of people  
who take tramadol succeed on delayed ejaculation . 
The Xiong  GG et al (2011) confirm that using of 50mg of tramadol and behavioral 
modification have an effect of treatment of premature ejaculation , on this study the 
researcher assigned two group one of them are control group , and the researchers apply 
the treatment of tramadol on one group and behavioral modification on control group 
with closed monitoring of kidney and hepatic functions , the result show that efficacy of 
tramadol for treatment of premature ejaculation with behavioral modification without 
effect on kidney and hepatic function.  
The Bar-Or D et al(2011) confirm that using of oral administer tramadol with low dose 
62mg can help people who are suffer from premature ejaculation . 
All of Kaynar M et al (2012) , Xiong  GG et al (2011) ,and Bar-Or D et al(2011) are 
agree that tramadol with low dose can help in treatment of premature ejaculation, 
without any effect on renal and hepatic function . 
The Emamhadi M et al (2012) confirm that tramadol toxicity can cause seizures by 
making disturbance in calcium & sodium channels . 
The Yarkan et al(2011) show that tramadol administration have an incidence to cause 
epileptic fit even in recommended dose that tramadol exerts a seizurogenic effect on 
mice via an H(1) receptor activation-linked pathway possibly through an opioid 
receptor-dependent release of histamine from the mast cells . 
The Afshari R& Ghooshkhanehee H (2009) was write a report about addict person who 




The  Talaie H et al (2009 ) confirm that  tramadol intake does not differ between 
patients with and without seizure, and the most common dose range in those with 
seizure is 500-1000 mg. We thus conclude that the incidence of seizure with tramadol is 
not dose dependent . 
The Sansone RA et al(2009) show that the use and abuse of tramadol can be cause 
seizures and serotonin syndrome . 
The Shadnia S et al (2008 ) show that tramadol have high incidence of intoxication after 
abused and occurrence of seizures and the fatal dose is 5000mg . 
The Jovanović-Cupić V et al (2006) confirm that The neurotoxicity of tramadol 
commonly manifests as generalized tonic-clonic seizures occurring most frequently 
within 24 h after tramadol intake. Seizures were more common in younger abusers with 
a longer duration of exposure to tramadol and with the combined use of tramadol with 
alcohol the dose range between 250- 2500mg. 
The Tobias JD (1997) confirm that tramadol intoxication cause tonic clonic convulsions  
All of The Emamhadi M et al (2012) , Yarkan et al(2011, Afshari R& Ghooshkhanehee 
H (2009), Talaie H et al (2009 ), Sansone RA et al(2009) , Shadnia S et al (2008 ) , 
Jovanović-Cupić V et al (2006) , and Tobias JD (1997) agree that intoxication of 
tramadol due to misuse can cause tonic clonic seizures . 
  The Lanier RK et al (2010) show that Chronic tramadol administration produces dose-
related opioid physical dependence without producing dose-related attenuation of 
agonist challenge effects. 
The Tjäderborn M et al (2009 ) show that  There is an occurrence of tramadol 
dependence in association with analgesic treatment within the recommended dose 
range. In susceptible patients a severe and serious dependence syndrome may develop. 
A history of abuse or use of a drug of abuse seems to be an important risk factor. 
The Pollice R et al(2008) have a report about tramadol addiction in old woman without 
a history of substance abuse. 
The Näslund S& Dahlqvist R(2003) show that persons who are treated with tramadol 
has high percentage tramadol abuse , and there are has already substance abuse . 
The Senay EC et al(2003) show that tramadol has potential to induce withdrawal of the 
classical opioid type, and that atypical withdrawal may also occur.  
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The Liu ZM(1999) confirm that tramadol produced high abuse potential among opiate 
addicts. 
All of the Lanier RK et al (2010), Tjäderborn M et al (2009 ) , Pollice R et al(2008) , 
Näslund S& Dahlqvist R(2003) , Senay EC et al(2003) ,and Liu ZM(1999) agree that 

































 Study Design 
 Study Population  
 Study Sample  
 Study Tools  
 Pilot Study  




This chapter describes the methodology that was used in this research. The adopted 
methodology to accomplish this study uses the following techniques: the information 
about the research design, research population, questionnaire design, statistical data 
analysis, content validity, place of the study , illegibility criteria , ethical considerations, 
and pilot study. 
  
3.1.1Study Design 
The design of this study is descriptive, analytical, cross sectional study as it assesses the  
Knowledge, attitude, practice, psychological state , and presence of side effects of 
tramadol abusers .Cross sectional study was chosen because it appropriate for 
describing the status of phenomena or for describing relationships among phenomena at 
fixed point in time.                                                                                                                
The first phase of the research thesis proposal included identifying and defining the 
problems and establishment objective of the study and development research plan. 
 The second phase of the research included a summary of the comprehensive literature 
review. Literatures on claim management was reviewed.  
 The third phase of the research included a field survey which was conducted with the 
study of  " assess the abuse of tramadol among persons who have tramadol abuse by 
examine the level of knowledge, attitude, and practice " 
The fourth phase of the research focused on the modification of the questionnaire 
design, through distributing the questionnaire to pilot study, The purpose of the pilot 
study was to test and prove that the questionnaire questions are clear to be answered in a 
way that help to achieve the target of the study. The questionnaire was modified based 
on the results of the pilot study.  
The fifth phase of the research focused on distributing questionnaire. This 
questionnaire was used to collect the required data in order to achieve the research 
objective. 
The sixth phase of the research was data analysis and discussion. Statistical Package 
for the Social Sciences, (SPSS) was used to perform the required analysis. The final 
phase includes the conclusions and recommendations. 
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A one hundred and twenty questionnaires were distributed to the research population 
and one hundred  questionnaires are received.  
 
Figure (1) shows the methodology flowchart, which leads to achieve the research 
objective. 
    
Research methodology  
3.1.2 Data Collection Methodology  
In order to collect the needed data for this research , we use the secondary resources in 
collecting data such as books, journals, statistics and web pages , in addition to 
preliminary resources that not available in secondary resources through distribute 
questionnaires on study population in order to get their opinions about the " assess the 
abuse of tramadol among persons who have tramadol abuse by examine the level of 
knowledge, attitude, and practice ". Research methodology depend on the analysis of      
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The study population of this study in not defined , and there is no statistical report about  
the number of tramadol abusers , the researcher select two famous private psychiatric    
clinics to take the study sample.        
The study population of the present work is all males and females  they  recorded  and  
treated as tramadol abusers on the two private  psychiatric clinics in Gaza city .         
 
3.1.4Sample size and sampling procedure 
The researcher have an approval from the directors of the two private psychiatric clinics 
to apply the study in their  clinics ,and  by assessment about the number of clients who 
are attend the clinics to recover from tramadol  every day , there is 4-6 client attend 
clinics daily .  
From the viewpoint of the researcher The sample size of the present study will be 
calculated by collecting the sample on one month in the two private psychiatric clinics 
as 4 cases in every day during the month, and questionnaires were distributed to the 
convenient  sample and 100 questionnaires are received . 
 
3.1.5 Place of study: 
This study was carried out in the two private  psychiatric clinics in Gaza city with 
sample size relatively compatible, as much as possible,  with the population size of each 
clinic. 
The two psychiatric clinics are following to the Dr ayesh samour and Dr mohammed 
abu sebah .The two doctors are working on Palestinian ministry of health on general 
directory of mental health , and  eternally their consent to apply the study in their 
clinics. 
 
3.1.6 Period of study: 
The study started when the researcher have approval from seminar committee  and 




3.1.7 Eligibility criteria: 
3.1.7.1 Inclusion criteria: 
All males and females they recorded and treated as tramadol abusers , and age from 16-
50 years old ,and they are abused tramadol daily. 
 
3.1.7.2 Exclusion criteria: 
Any client who treated for other psychiatric disorders. 
3.1.8 Ethical consideration : 
Approval from each person who will participate in the study. 
Approval from Islamic university about the study . 
Approval from Dr.Ayesh samuor(Annex1 ). 
Approval from Dr.Mohammed abu sebah(Annex 2). 
 
3.2 Questionnaire content  
One   questionnaire was provided with a covering letter explaining the purpose of the 
study, the way of responding, the aim of the research and the security of the information 
in order to encourage a high response. The questionnaire included multiple choice 
question: which used widely in the questionnaire, The variety in these questions aims 
first to meet the research objectives, and to collect all the necessary data that can support 
the discussion, results and recommendations in the research.   
The sections in the questionnaires will verify the objectives in this research related to 
measure the " assess the abuse of tramadol among persons who have tramadol abuse by 
examine the level of knowledge, attitude, and practice  as follows 
First section : personal data consist from 8 Sentences. 
second section: Knowledge of tramadol abusers consist from 13 Sentences. 
third section :  Practices of tramadol abusers consist from 24 Sentences. 
forth section : Attitudes  of tramadol abusers consist from 17 Sentences. 
fifth section : The psychological state of the abusers before abused tramadol consist 
from 5 Sentences. 
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Sixth section : The presence of side effects of the abuse of tramadol consist from 9 
Sentences. 




Disagree Hesitant Agree Strongly agree 
Scale 1 2 3 4 5 
 
3.3 Pilot Study                             
A pilot study for the questionnaire was conducted before collecting the results of the 
sample. It provides a trial run for the questionnaire, which involves testing the wordings 
of question, identifying ambiguous questions, testing the techniques that used to collect 
data, and measuring the effectiveness of standard invitation to respondents . 
Twenty five of questionnaires were distributed for this goal and the result of pilot study 
have few modifications don on the questionnaire and the pilot study sample were 
excluded from the study sample .  
3.4Validity of the Tool                               
We can  define the validity of an instrument as a determination of the extent to which 
the instrument actually reflects the abstract construct being examined. "Validity refers 
to the degree to which an instrument measures what it is supposed to be measuring". 
High validity is the absence of systematic errors in the measuring instrument. When an 
instrument is valid; it truly reflects the concept it is supposed to measure. Achieving 
good validity required  the care  in the research design and sample selection . The 
amended questionnaire was  by the supervisors and five expertise in the tendering and 
bidding environments to evaluate the procedure of questions and the method of 
analyzing the results. The expertise agreed that the questionnaire was valid and suitable 
enough to measure  the purpose that the questionnaire designed for. 
 
3.4.1Content Validity of the Questionnaire                          
Content validity test was conducted by consulting one groups of experts. They was 
requested to evaluate and identify whether the questions agreed with the scope of the 
items and the extent to which these items reflect the concept of the research problem. 
The other was requested to evaluate that the instrument used is valid statistically and 
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that the questionnaire was designed well enough to provide relations and tests between 
variables. The group of experts did agree that the questionnaire was valid and suitable 
enough to measure the concept of interest with some amendments.     
3.4.2 Statistical Validity of the Questionnaire                          
To insure the validity of the questionnaire, two statistical tests should be applied. The 
first test is Criterion-related validity test (Pearson  test) which measure the correlation 
coefficient between each item  in the field and the whole field. The second test is 
structure validity test (Pearson test) that used to test the validity of the questionnaire 
structure by testing the validity of each field and the validity of the whole questionnaire. 
It measures the correlation coefficient between one filed and all the fields of the 
questionnaire that have the same level of similar scale.  
 3.4.2.1 Criterion Related Validity : 
3.4.2.1.1 Internal consistency:              
Internal consistency of the questionnaire is measured by a scouting sample, which 
consisted of twenty  five questionnaires, through measuring the correlation coefficients 
between each paragraph in one field and the whole filed. Tables No. (1) below shows 
the correlation coefficient and p-value for each field items. As show in the table the p- 
Values are less than 0.05 or 0.01,so the correlation coefficients of this field are 
significant at α = 0.01 or  α = 0.05,  so it can be said that the paragraphs of this field are 
consistent and valid to be measure what it was set for. 
Table(1) 
The correlation coefficient between each paragraph in the field and the whole field 






1 DO you Know tramadol 0.449 0.015 
2 
Do you  Believe that the abuse of tramadol, is a 
problem in the Gaza Strip 
0.529 0.004 
3 




Do you Believe that, taking tramadol affects the 
persons daily life 
0.623 0.000 
5 Do you Know that the tramadol is a pain reliever. 0.546 0.002 
6 
Do you Believe that the widespread misuse tramadol is 
an impact  of the siege. 
0.476 0.009 
7 
 Do you Believe that taking tramadol, affects the 
sexual life. 
0.571 0.001 





The correlation coefficient between each paragraph in the field and the whole field 




p-value Statement No. 
0.000 0.743 Can you get tramadol from pharmacies easily . 1 
0.000 0.628 Can you get tramadol from drug dealers . 2 
0.002 0.556 Can you get tramadol from friends . 3 
0.000 0.635 
Can you get tramadol from those who work in the 
tunnels  . 
4 
0.000 0.707 Did you use tramadol to treat premature ejaculation . 5 
0.000 0.760 Did tramadol help you to delay ejaculation. 6 
0.000 0.693 




Did you use tramadol while you did not suffer from 
premature ejaculation. 
8 
0.000 0.646 Did you use tramadol in order to stay late . 9 
0.000 0.680 Did you start taking pills of 100mg. 10 
0.000 0.682 
Did you increase taking the number of pills from time 
to time  . 
11 
0.000 0.695 Did you use tramadol to reach the state of euphoria  12 
9 




Did your work was affected due to using tramadol 
negatively .  
0.642 0.000 
11 




Do you  Believe that the misusing tramadol is 
religiously for bidden. 
0.684 0.000 
13 





0.000 0.663 Did you use tramadol to help you in your work . 13 
0.000 0.684 Did you take tramadol at the same time of the last dose. 14 
0.000 0.717 Did you do any illegal action to get tramadol . 15 
0.001 0.575 
Did the effect of tramadol was affected with the 
amount and the number of pills  
16 
0.020 0.431 Did you use tramadol  to help in your study. 17 
0.000 0.622 
Did you use tramadol to help you in increasing your 
physical efforts in parties . 
18 
0.000 0.621 Did you take tramadol  during pregnancy. 19 
0.003 0.530 Are you smoking . 20 
0.008 0.486 Are you a heavy smoker . 21 
0.000 0.678 
Did the use of tramadol affect in increasing the number 
of cigarettes and change the euphoria of smoking. 
22 
0.000 0.680 Do you take alcoholic drinks 23 




The correlation coefficient between each paragraph in the field and the whole field 
(Attitudes  of tramadol abusers) 
Pearson 
coefficient 
p-value Statement No. 
0.000 0.719 
Do you Support the measures of concerned 
people  to stop the spread of this phenomenon. 
1 
0.000 0.651 
Do you support programs of mass media to stop 
the spared of this phenomena.  
2 
0.004 0.554 







Did you try stop using tramadol due to the 
hardness of getting it. 
4 
0.000 0.673 




Was there any one who expected that you were 
taking tramadol . 
6 
0.000 0.746 








Were you exposed to confrontation or 
embarrassments due to taking tramadol . 
9 
0.000 0.659 Did you  Try to stop on your own. 10 
0.000 0.700 Were you  engaged in a treatment program. 11 
0.000 0.706 




Were you able to get rid of the using tramadol for 
more than a month. 
13 
0.000 0.646 Were you able  to stop taking tramadol. 14 
0.000 0.745 




Are the  reasons behind stopping the use of 
tramadol social . 
16 
0.001 0.604 
Are the  reasons behind stopping the use of 
tramadol economic . 
17 
0.001 0.634 
Are the  reasons behind stopping the use of 








The correlation coefficient between each paragraph in the field and the whole field 
(The psychological state of the tramadol abusers) 
Pearson 
coefficient 
p-value Statement No. 
0.015 0.534 
Did you take this drug while you were suffering 
from psychological stress. 
1 
0.000 0.812 Were  you suffering  from anxiety. 2 
0.004 0.557 Were you suffering  from a sleep disorder. 3 
0.004 0.556 Did you deal with tramadol to escape from reality  4 






The correlation coefficient between each paragraph in the field and the whole field 
(The presence of side effects related to abuse of tramadol) 
Pearson 
coefficient 
p-value Statement No. 
0.006 0.537 
Did you  suffered from gastrointestinal disorders 
that caused by abuse  of tramadol .  
1 
0.001 0.616 
Did you  suffer from convulsions or coma that 
caused by the abuse of tramadol . 
2 
0.006 0.533 
Did you  Suffer from itching  feeling in the feet or 
electrical waves during the misusing tramadol. 
3 
0.003 0.571 
Did you  Suffer from a rise in body temperature 
during the abuse of tramadol . 
4 
0.012 0.495 
Did you  Suffer from tremor when you did not 
use tramadol . 
5 
0.000 0.649 












Did you have  high blood pressure 
 when you stop using tramadol . 
8 
0.001 0.616 




3.6.1.2 Structure Validity of the Questionnaire    
Structure validity is the second statistical test that used to test the validity of the 
questionnaire structure by testing the validity of each field and the validity of the whole 
questionnaire. It measures the correlation coefficient between one filed and all the fields 
of the questionnaire that have the same level of likert  scale.  
As shown in table No. (6), the significance values are less than 0.05 or 0.01, so the 
correlation coefficients of all the fields are significant at α = 0.01 or  α = 0.05,  so it can 
be said that the fields are valid to be measured what it was set for to achieve the main 
aim of the study  . 
 
Table No. (6) 








Knowledge of tramadol abusers 
0.701 0.000 
2 
Practices of tramadol abusers 
0.805 0.000 
3 
Attitudes  of tramadol abusers 
0.687 0.000 
4 
The psychological state of the abusers of tramadol 
0.742 0.000 








3.7 Reliability of the Tool                             
Reliability of an instrument is the degree of consistency with which it measures the 
attribute it is supposed to be measuring . The test is repeated to the same sample of 
people on two occasions and then compares the scores obtained by computing a 
reliability coefficient. For the most purposes reliability coefficient above 0.7 are 
considered satisfactory. Period of two weeks to a month is recommended between two 
tests Due to complicated conditions that the contractors is facing at the time being, it 
was too difficult to ask them to responds to our questionnaire twice within short period. 
The researcher  explained that, overcoming the distribution of the questionnaire twice  
to measure the reliability can be achieved by using cronbach Alpha coefficients and 
Half Split Method through the SPSS software. 
 
3.7.1 Half Split Method                           
This method depends on finding Pearson correlation coefficient between the means of 
odd rank questions and even rank  questions of each field of the questionnaire. Then, 
correcting the Pearson correlation coefficients can be done by using Spearman Brown 
correlation coefficient of correction. The corrected correlation coefficient ( consistency 
coefficient) is computed according to the following equation :  
Consistency coefficient = 2r/(r+1), where r is the Pearson correlation coefficient. The 
normal range of corrected correlation coefficient 2r/(r+1) is between 0.0 and + 1.0 As 
shown in Table No.(7), all the corrected correlation coefficients values are between 
0.8085 and 0.8785 and the general reliability for all items equal 0.8408 , and the 
significant (α ) is less than 0.05 so all the corrected correlation coefficients are 
significance at α = 0.05. It can be said that according to the Half Split method, the 
dispute causes group are reliable.    
Table (7) 









1 Knowledge of tramadol 
abusers. 
0.7424 0.8521 0.000 
2 Practices of tramadol 
abusers. 











3 Attitudes  of tramadol 
abusers. 
0.6785 0.8085 0.000 
4 
The psychological state of 
the tramadol abusers . 
 
 
0.7832 0.8785 0.000 
5 
The presence of side 
effects related to tramadol 
abuse. 
0.7143 0.8333 0.000 
 Total  0.7254 0.8408 0.000 
 
 
3.7.2 Cronbach’s Coefficient Alpha                            
 
This method is used to measure the reliability of the questionnaire between each field 
and the mean of the whole fields of the questionnaire. The normal range of  Cronbach‘s 
coefficient alpha value between 0.0 and + 1.0, and the higher values reflects a higher 
degree of internal consistency. As shown in Table No. (8) the Cronbach‘s coefficient 
alpha was calculated for the first field of the causes of  claims,  the second field of 
common procedures and the third field of the Particular claims. The results were in the 
range from 0.8267and 0.8925,  and the general reliability for all items equal 0.8633. 











Knowledge of tramadol abusers. 
13 0.8364 
2 
Practices of tramadol abusers. 
24 0.8456 
3 









4 The psychological state of the tramadol 
.abusers  
5 0.8925 
5 The presence of side effects related to 
tramadol abuse . 
9 0.8513 





To achieve the research goal, researcher used the statistical package for the Social 
Science  (SPSS) for Manipulating and analyzing the data. 
 
Statistical methods are as follows   
 
1- Frequencies and Percentile 
2- Alpha- Cronbach Test for measuring reliability of the items of the questionnaires 
3- Person correlation coefficients for measuring validity of the items of the 
questionnaires. 
4- spearman –Brown Coefficient 
5- one sample t test 
6-independent samples T test 
7- one way ANOVA test 





































4.1 One Sample K-S Test 
One Sample K-S test will be used to identify if the data follow normal distribution or 
not, this test is considered necessary in case testing hypotheses as most parametric Test 
stipulate data to be normality distributed and this test used when the size of the sample 
are greater than 50. Results test as shown in table (9) , clarifies that the calculated p-
value is greater than the significant level which is equal 0.05 ( p-value. > 0.05), this in 
turn denotes that data follows normal distribution, and so parametric Tests  must be 
used. 
Table (9) 
One Sample K-S 
 Section  
Statistic P-value 
1 
Knowledge of tramadol abusers 
13 0.940 0.340 
2 
Practices of tramadol abusers 
24 0.919 0.367 
3 
Attitudes  of tramadol abusers 
18 0.767 0.598 
4 
The psychological state of the abusers of tramadol 
5 1.083 0.191 
5 
The presence of side effects related to abuse of  tramadol. 
9 1.052 0.218 
 
All sections  
69 1.248 0.089 
 
4.2 Discussion of Research Question   
We use a one sample t test to test if the opinion of the respondent in the content of  the 
sentences are positive ( weight mean greater than "60%" and the p-value less than 0.05) 
or the opinion of the respondent in the content of the sentences are neutral ( p- value is 
greater than 0.05) or the opinion of the respondent in the content of the sentences are 
negative (weight mean less than "60%" and the p-value less than 0.05) . 
4.2.1Section one: Personal information    
1-Age 
Table No.(10) show that 42.0% from the samples age " less than 25years   " , and  38.0% 
from the samples age " from 25-30  year " , and  20.0 % from the samples age " more 








Frequency  Percentages  
less than 25 years    
42 42.0 
from 25-30 year 
38 38.0 





2-Sex :    
Table No.(11) show that  89.0% from the samples are " male" , and 14.0% from the 
samples are " female" , this attributed to the seriousness of this phenomenon, as the 
abuse of Tramadol is not limited to men, but that there are ladies slating tramadol , and 















3- Address : 
Table No.(12) show that 18.0% from the samples from " North governorate ", and 
52.0% from the samples from " Gaza governorate ", and   18.0% from the samples from 
" Middle governorate ", and    9.0% from the samples from " Khan yunis  governorate ", 


















100      100.0     
4- Marital Status 
Table No.(13) show that 38.0% from the sample are " Single " , and 57.0% from the 















                                                       
5- Number of family members who live with you in the same house  
Table No.(14) show that 25.0% from the sample Number of family members who live 
with you in the same house " Less than 5 members " , and 63.0% from the sample 
Number of family members who live with you in the same house "5-10 members " , and 
12.0% from the sample Number of family members who live with you in the same 
house " More than 10 members ". 
Table No.(14) 
Number of family members who live with you in the same house 
Number of family members who live 
 with you in the same house 
Frequency  Percentages  











6-Monthly income of NIS: 
"  y income of NISMonthl) show that 51.0% from the sample the  15Table No.(
 Monthly income of NIS% from the sample the  " , and 35.0 1000 NISLess than
"  Monthly income of NIS% from the sample the  " , and 12.0 2000 NIS-1000" 
2100- 3000 NIS " , and 
2.0% from the sample the  Monthly income of NIS " 3100 NIS and above " .  
Table No.(15) 
Monthly income of NIS 
Monthly income of NIS 
Frequency  Percentages  




2100- 3000 NIS 
12 12.0 





7- Scientific level: 
Table No.(16) show that 22.0% from the sample the Scientific level are " Less than 
High School " , and 25.0% from the sample the Scientific level are " High School " , 
and  17.0% from the sample the Scientific level are " Diploma of two years " , and   




Frequency  Percentages  














    
 
8-Profession : 
Table No.(17) show that 25.0% from the sample's Profession are " Employee " , and   
25.0% from the sample's Profession are " Worker " , and   22.0% from the sample's 
Profession are " Student " , and   23.0% from the sample's Profession are " Unemployed 


















4.2.2Section two: Knowledge of tramadol  abusers  
We use a one sample t test to test if the opinion of the respondent  about Knowledge of 
tramadol  abusers and the results shown in  Table  No. (18) as follows:  
The three highest statements according to weight mean as follows: 
1. In item No. ( 2) the weight mean equal   " 96.40%" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample Believe that the using of tramadol, 
is a problem in the Gaza Strip),  this result can be explained that there is a spread 
of this phenomenon in the Gaza Strip, and this is consistent with a study (Afifi et 
al, 2005), where the study explain the prevalence rates of drug abuse among 
universities students in the Gaza Strip. 
2. In item No. (1) the weight mean equal   " 94.80%" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample Know tramadol). 
3. In item No. (9) the weight mean equal  " 94.40%" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample Believe that the abuse of tramadol 
cause addiction), this result confirm that abuse of tramadol has high potential to 
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cause dependence , and this consistent with a study of (Liu ZM;1999) where the 
study confirm that tramadol has high potential abuse among  addicts persons .and 
also this result consistent with the study of (Tjäderborn M et al ;2009 ) where the 
study explain the result of tramadol dependence in Sweden and explain the 
dependence dose that cause adverse drug reactions .   
And the three lowest  statements according to weight mean as follows 
1- In item No. (11) the weight mean equal " 66.00%" and p-value equal "0.078 " 
which is greater than 0.05, that means (the sample Believe that work was affected 
due to using tramadol positively moderately). 
2- In item No. (10) the weight mean equal " 62.60%" and p-value equal " 0.431" 
which is greater than 0.05, that means (the sample Believe that work was affected 
due to using tramadol negatively moderately). 
3- In item No.(12 ) the weight mean equal "  62.40%" and p-value equal "0.790" 
which is greater than 0.05, that means (the sample Believe that the misusing 
tramadol is religiously for bidden moderately) this result can be explained that 
there is lack of  . 
For general the results for all  items of the field show that the average mean equal  
4.09  and the weight mean equal 81.86  % which is  greater  than  " 60%"  and the 
value of t test equal  26.482 which is greater than the critical value which is equal 
1.98  and the p- value equal 0.000  which is less  than 0.05, that means the sample 
has good knowledge about tramadol at significant    level 05.0 . 
Table No.(18) 












DO you Know tramadol 
 
 
4.74 0.613 94.80 28.370 0.000 
2 
Do you  Believe that the 
abusing   of tramadol, is a 
problem in the Gaza Strip 
4.82 0.575 96.40 31.639 0.000 
3 
Do you Believe that there is a 
certain groupmisuses tramadol. 
4.19 1.070 83.80 11.119 0.000 
4 
Do you Believe that, taking 
tramadol affects the persons 
daily life 




Do you Believe that the 
widespread misuse tramadol is 
an impact  of the siege. 
4.48 0.979 89.60 15.112 0.000 
7 
 Do you Believe that taking 
tramadol, affects the sexual 
life. 
4.41 0.911 88.20 15.475 0.000 
8 
Were you aware of this drug 
doses when you take it . 
4.25 0.999 85.00 12.516 0.000 
9 
Do you  Believe that the 
misuse of tramadol causes 
addiction. 
4.72 0.668 94.40 25.753 0.000 
10 
Did your work was affected 
due to using tramadol 
negatively .  
3.13 1.643 62.60 0.791 0.431 
11 
Did your work was affected 
due to using tramadol 
positively . 
3.30 1.685 66.00 1.781 0.078 
12 
Do you  Believe that the 
misusing tramadol is 
religiously for bidden. 
3.12 1.731 62.40 0.693 0.490 
13 
Do you  Believe that the 
smoking is religiously for 
bidden. 
3.69 1.316 73.80 5.244 0.000 
 All items 
4.09 0.413 81.86 26.482 0.000 
Critical value of t at df "99" and significance level 0.05 equal 1.98 
4.2.3 Section three : Practices of tramadol abusers 
We use a one sample t test to test if the opinion of the respondent  about Practices of 
tramadol abusers and the results shown in  Table  No. (19) as follows:  
The three highest statements according to weight mean as follows: 
1. In item No. (3 ) the weight mean equal   " 94.80%" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample get tramadol from friends) this 
result can be confirm that the get of tramadol is easily accessible to everyone. 
2. In item No. (12) the weight mean equal   " 92.60%" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample use tramadol to reach the state of 
euphoria) this result can be explained that tramadol has an effect on CNS Produces 
a state of euphoria and this consistent with study of(Liu ZM;1999) that confirm 
that abuse of tramadol produce euphoria   . 
3. In item No. (11) the weight mean equal  " 92.40%" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample  increase taking the number of pills 
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from time to time  ) this result can be explained that tramadol cause drug tolerance      
, Which is evident by the increase the number of pills from time to time to get the 
same result of the first dose  . 
Also the results show that the weight mean of item No(6) equal "79.40" that mean the 
tramadol help the sample to in delaying ejaculation , this mean that tramadol has an 
effect of delaying ejaculation , and this result consistent with the study of (Kaynar M et 
al ;2012) that confirm the On-demand use of low-dose tramadol is effective for lifelong 
PE , (Xiong  GG et al ;2011 ) that confirm the Tramadol hydrochloride with behavioral 
modification showed positive effects in prolonging and improving partners' intercourse 
satisfaction , (Bar-Or D et al;2011) that confirm the On-demand 62mg tramadol ODT is 
an effective treatment for PE in a low and safe therapeutic dose and provides anew 
option for managing mild to severe PE . 
In item No (20) the weight mean equal "79.20" mean that sample is smoke cigarettes , 
this explain the close association between smoking and abuse of tramadol , were the 
smoking is kind of addiction . 
In item No"15" the weight mean equal "63.40" has illegal action to get tramadol , the 
researcher observe that the main illegal action is stealing .    
And the three lowest  statements according to weight mean as follows 
1. In item No. (17) the weight mean equal  "  51.60%" and p-value equal "0.008 " 
which is less  than 0.05, that means (tramadol  not help in your study). 
2. In item No. (24) the weight mean equal  "  45.20%" and p-value equal "0.000 " 
which is less  than 0.05, that means (not abuse another drug with tramadol). 
3. In item No.(23 ) the weight mean equal  "  33.00%"  and p-value equal " 0.000" 
which is less than 0.05, that means (the sample  not take alcoholic drinks) this 
result can be explained that the Palestinian community is Conservative society ,and 
muslim community and the Islamic religion prohibits drinking alcohol. 
For general the results for all  items of the field show that the average mean equal   
3.65 and the weight mean equal   72.98% which is  greater  than  " 60%"  and the 
value of t test equal  11.938 which is greater than the critical value which is equal 
1.98  and the p- value equal 0.000  which is less  than 0.05, that means   that the 






















Can you get tramadol from 
pharmacies easily . 
2.91 1.342 58.20 -0.671 0.504 
2 
Can you get tramadol from drug 
dealers . 
4.41 1.055 88.20 13.365 0.000 
3 
Can you get tramadol from 
friends . 
4.74 0.525 94.80 33.171 0.000 
4 
Can you get tramadol from 
those who work in the tunnels  . 
3.64 1.360 72.80 4.707 0.000 
5 
Did you use tramadol to treat 
premature ejaculation . 
3.42 1.485 68.40 2.828 0.006 
6 
Did tramadol help you to delay 
ejaculation. 
3.97 1.306 79.40 7.426 0.000 
7 
Did tramadol help you to take 
your time in delaying  
ejaculation. 
3.71 1.320 74.20 5.377 0.000 
8 
Did you use tramadol while you 
did not suffer from premature 
ejaculation. 
2.63 1.426 52.60 -2.595 0.011 
9 
Did you use tramadol in order 
to stay late . 
4.07 1.112 81.40 9.619 0.000 
10 
Did you start taking pills of 
100mg. 
4.31 1.032 86.20 12.697 0.000 
11 
Did you increase taking the 
number of pills from time to 
time  . 
4.62 0.749 92.40 21.625 0.000 
12 
Did you use tramadol to reach 
the state of euphoria . 
4.63 0.906 92.60 17.986 0.000 
13 
Did you use tramadol to help 
you in your work . 
3.72 1.356 74.40 5.308 0.000 
14 
Did you take tramadol at the 
same time of the last dose. 
4.17 1.111 83.40 10.535 0.000 
15 
Did you do any illegal action to 
get tramadol . 
3.17 1.484 63.40 1.145 0.255 
16 
Did the effect of tramadol was 
affected with the amount and 
the number of pills  
4.58 0.806 91.60 19.596 0.000 
17 









Did you use tramadol to help 
you in increasing your physical 
efforts in parties . 
 
 
3.92 1.323 78.40 6.952 0.000 
19 
Did you take tramadol  during 
pregnancy. 
2.94 0.722 58.80 -0.831 0.408 
20 
Are you smoking . 3.96 1.435 79.20 6.690 0.000 
21 
Are you a heavy smoker . 3.66 1.565 73.20 4.218 0.000 
22 
Did the use of tramadol affect in 
increasing the number of 
cigarettes and change the 
euphoria of smoking. 
3.91 1.615 78.20 5.635 0.000 
23 
Do you take alcoholic drinks 1.65 1.209 33.00 -11.165 0.000 
24 
Did you abuse  another drug 
with tramadol. 
2.26 1.411 45.20 -5.243 0.000 
 All items 
3.65 0.544 72.98 11.938 0.000 
Critical value of t at df "99" and significance level 0.05 equal 1.98 
4.2.4 Section four : Attitudes  of tramadol abusers 
We use a one sample t test to test if the opinion of the respondent  about Attitudes  of 
tramadol misusers and the results shown in  Table  No. (20) as follows:  
The three highest statements according to weight mean as follows: 
1. In item No. (18 ) the weight mean equal   " 89.00%" and p-value equal " 0.000" 
which is less than 0.05, that means (the  reasons behind stopping the use of 
tramadol healthy) this result can be explained that abusers complain of medical 
problem as related to abuse a high amount of tramadol , and this result consistent 
with study of (Shadnia S, et al 2008 ) that explain the common effect of tramadol 
intoxication  . 
2. In item No. (2) the weight mean equal   " 87.60%" and p-value equal " 0.000" 
which is less than 0.05, that means ( the sample support programs of mass media 
to stop the spared of this phenomena). 
3. In item No. (11) the weight mean equal  " 85.40%" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample engaged in a treatment program). 
And the three lowest  statements according to weight mean as follows 
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1. In item No. (9) the weight mean equal  "  69.60%" and p-value equal " 0.001" 
which is less  than 0.05, that means (the sample exposed to confrontation or 
embarrassments due to taking tramadol). 
2. In item No. (5) the weight mean equal  "  67.20%" and p-value equal "0.020 " 
which is less  than 0.05, that means (the sample feels of  the stigma because of 
taking  tramadol).  
3. In item No.( 4) the weight mean equal  "  65.40%" and p-value equal "0.070 " 
4. which is greater than 0.05, that means (the sample  try  moderately stop using 
tramadol due to the hardness of getting it). 
For general the results for all  items of the field show that the average mean equal   
3.87 and the weight mean equal   77.47% which is  greater  than  " 60%"  and the 
value of t test equal  12.568 which is greater than the critical value which is equal 
1.98  and the p- value equal 0.000  which is less  than 0.05, that means    reasons 
behind stopping the use of tramadol, social , economic,  and  healthy at significant    
level 05.0  
Table No.(20) 












Do you Support the measures of 
concerned people  to stop the 
spread of this phenomenon. 
4.11 1.442 82.20 7.699 0.000 
2 
Do you support programs of mass 
media to stop the spared of this 
phenomena.  
4.38 1.187 87.60 11.623 0.000 
3 
Did you  try to stop the using 
tramadol due to some 
circumstances. 
3.90 1.210 78.00 7.437 0.000 
4 
Did you try stop using tramadol 
due to the hardness of getting it. 
3.27 1.476 65.40 1.829 0.070 
5 
Did you feel of  the stigma 
because of taking  tramadol . 




Was there any one who expected 
that you were taking tramadol . 
3.51 1.219 70.20 4.185 0.000 
7 
Did anyone around you suffer 
from your taking tramadol . 
 
3.68 1.302 73.60 5.224 0.000 
8 
Did you neglect your family 
because of using tramadol . 
3.53 1.494 70.60 3.548 0.001 
9 
Were you exposed to 
confrontation or embarrassments 
due to taking tramadol . 
3.48 1.337 69.60 3.590 0.001 
10 
Did you  Try to stop on your own. 4.15 0.978 83.00 11.755 0.000 
11 
Were you  engaged in a treatment 
program. 
4.27 1.033 85.40 12.290 0.000 
12 
Were you Committed to the 
instructions of the treatment 
program. 
4.13 1.152 82.60 9.812 0.000 
13 
Were you able to get rid of the 
using tramadol for more than a 
month. 
4.09 1.303 81.80 8.363 0.000 
14 
Were you able  to stop taking 
tramadol. 
3.77 1.448 75.40 5.316 0.000 
15 
Are the  reasons behind stopping 
the use of tramadol, religious. 
3.49 1.630 69.80 3.006 0.003 
16 
Are the  reasons behind stopping 
the use of tramadol social . 
4.04 1.406 80.80 7.394 0.000 
17 
Are the  reasons behind stopping 
the use of tramadol economic . 
4.11 1.348 82.20 8.237 0.000 
18 
Are the  reasons behind stopping 
the use of tramadol healthy . 
4.45 1.104 89.00 13.129 0.000 
 
All sentences  3.87 0.695 77.47 12.568 0.000 
Critical value of t at df "99" and significance level 0.05 equal 1.98 
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4.2.5 Section five : The psychological state of the abusers of tramadol 
We use a one sample t test to test if the opinion of the respondent  about The 
psychological state of the abusers of tramadol and the results shown in  Table  No. 
(21) according to weight mean  from highest to lowest  as follows:  
1. In item No. (1 ) the weight mean equal   " 82.80%" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample takes this drug while you were 
suffering from psychological stress). 
2. In item No. (2) the weight mean equal   " 80.60%" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample suffering  from anxiety). 
3. In item No. (4) the weight mean equal  " 78.40%" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample deals with tramadol to escape from 
reality). 
4. In item No. (5) the weight mean equal  " 77.20%" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample use tramadol to avoid social 
problems). 
5. In item No. (3) the weight mean equal  " 62.20%" and p-value equal " 0.441" which 
is greater than 0.05, that means (the sample suffering moderately from a sleep 
disorder). 
For general the results for all  items of the field show that the average mean equal 
3.81  and the weight mean equal   76.24% which is  greater  than  " 60%"  and the 
value of t test equal 7.972 which is greater than the critical value which is equal  
1.98  and the p- value equal  0.000  which is less  than 0.05, that means The 
psychological state of the misusers of tramadol unstable at significant    
level 05.0 , and this can be explained that unstable psychological state for persons 
may increase the risk of substance abuse .  
 
Table No.(21) 












Did you take this drug while you 
were suffering from 
psychological stress. 
4.14 1.271 82.80 8.966 0.000 
2 
Were  you suffering  from 
anxiety. 
4.03 1.275 80.60 8.079 0.000 
3 
Were you suffering  from a sleep 
disorder. 




Did you deal with tramadol to 
escape from reality . 
3.92 1.323 78.40 6.952 0.000 
5 
Did you use tramadol to avoid 
social problems . 
3.86 1.271 77.20 6.764 0.000 
 All items 
3.81 1.019 76.24 7.972 0.000 
Critical value of t at df "99" and significance level 0.05 equal 1.98 
4.2.6 Section sixth  : The presence of side effects of the abuse of tramadol. 
We use a one sample t test to test if the opinion of the respondent  about The presence of 
side effects of the misuse of tramadol and the results shown in  Table  No. (22) as 
follows:  
The three highest statements according to weight mean as follows: 
1. In item No. ( 7) the weight mean equal   " 90.00%" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample have  physical symptoms when you 
stop using tramadol), this result can explained that tramadol cause addiction , and 
the interruptions cause the presence of withdrawal symptoms ,and this result 
consistent with study of (Senay EC et al;2003) that confirm the tramadol has 
withdrawal symptom like opiates. In most cases, the withdrawal symptoms 
consisted of classical opioid withdrawal, but in some cases were accompanied by 
withdrawal symptoms not normally observed in opiate withdrawal, such as 
hallucinations, paranoia, extreme anxiety, panic attacks, confusion and unusual 
sensory experiences such as numbness and tingling in one or more extremities.   
2. In item No. (3) the weight mean equal   85.60" %" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample Suffer from itching  feeling in the feet 
or electrical waves during the misusing tramadol). 
3. In item No. (1) the weight mean equal  " 85.40%" and p-value equal " 0.000" 
which is less than 0.05, that means (the sample suffered from gastrointestinal disorders 
that caused by abuse of tramadol) this can be explained that intoxication of tramadol 
affect many centers on the brain , this result consistent with study of(Shadnia S et 
al 2008 ) that confirm the Tramadol overdose has been one of the most frequent 
causes of drug poisoning in his country in the recent years, especially in male 
young adults with history of substance abuse and mental disorders. Nausea, 
vomiting, Central Nervous System (CNS) depression, tachycardia, and seizure are 
the most common findings in this kind of poisoning. Cardiopulmonary arrest was 
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found as the cause of death in cases who had ingested more than 5000 mg 
tramadol.   
And the three lowest  statements according to weight mean as follows 
1. In item No. (2) the weight mean equal  "  71.80%" and p-value equal " 0.000" 
which is less  than 0.05, that means (the sample suffer from convulsions or coma 
that caused by the misuse of tramadol) this result can be explained that tramadol 
has an effect on CNS and abuse it may cause epileptic fits , and this attributed to 
ingestion of large amount of tramadol , this result consistent with study of 
(Jovanović-Cupić V et al ;2006) which confirm that The neurotoxicity of tramadol 
commonly manifests as generalized tonic-clonic seizures occurring most 
frequently within 24 h after tramadol intake. Seizures were more common in 
younger abusers with a longer duration of exposure to tramadol and with the 
combined use of tramadol , also study of(Talaie H et al ;2009 ) which confirm that 
incidence of seizures not depend on dose dependent ,  also(Tobias JD ;1997) report 
the occurrence of seizure activity after the inadvertent administration of 4 mg/kg of 
tramadol to a child. Previous reports of seizure activity after tramadol 
administration . 
2. In item No. (4) the weight mean equal  "  67.00%" and p-value equal " 0.018" 
which is less  than 0.05, that means (the sample Suffer from a rise in body 
temperature during the abuse of tramadol). 
3. In item No.( 8) the weight mean equal  "  60.60%"  and p-value equal 0.834" " 
which is greater than 0.05, that means  (the sample have  high blood pressure when 
you stop using tramadol moderately ). 
For general the results for all  items of the field show that the average mean equal   
3.84 and the weight mean equal   76.80% which is  greater  than  " 60%"  and the 
value of t test equal  12.276which is greater than the critical value which is equal 
1.98  and the p- value equal 0.000  which is less  than 0.05, that means there are 
side of effects of the abuse of tramadol at significant    level 05.0  
Table No.(22) 












Did you  suffered from 
gastrointestinal disorders that 
caused by abuse of tramadol .  
 




Did you  suffer from convulsions 
or coma that caused by the abuse 
of tramadol . 
3.59 1.609 71.80 3.668 0.000 
3 
Did you  Suffer from itching  
feeling in the feet or electrical 
waves during the abusing 
tramadol. 
 
4.28 1.138 85.60 11.250 0.000 
4 
Did you  Suffer from a rise in 
body temperature during the abuse 
of tramadol . 
3.35 1.452 67.00 2.410 0.018 
5 
Did you  Suffer from tremor when 
you did not use tramadol . 
3.84 1.339 76.80 6.274 0.000 
6 
Did you feel dizzy while you were 
taking tramadol . 
3.84 1.277 76.80 6.578 0.000 
7 
Did you have  physical symptoms 
when you stop using tramadol. 
4.50 0.937 90.00 16.001 0.000 
8 
Did you have  high blood pressure 
 when you stop using tramadol . 
3.03 1.425 60.60 0.211 0.834 
9 
Did you have  excessive sweating 
when you stop using tramadol. 
3.86 1.206 77.20 7.130 0.000 
 All items 
3.84 0.684 76.80 12.276 0.000 
Critical value of t at df "99" and significance level 0.05 equal 1.98 
 
All the items  
We use a one sample t test to test the opinion of the respondent  about the assess the 
abuse of tramadol among persons who have tramadol abuse by examine the level of 
knowledge, attitude, and practice  and the results shown in  Table  No. (23 ) which 
show that the average mean for all dimensions equal    3.83 and the weight mean 
equal   76.56% which is  higher  than  " 60%"  and the absolute value of t test 
equal  24.291which is greater than the critical value which is equal  1.98  and the p- 
value equal   0.000 which is less  than 0.05, that mean the assess the abuse of 
tramadol among persons who have tramadol abuse by examine the level of 
knowledge, attitude, and practice this means that the sample had good knowledge 
about tramadol ,were the sample aware that tramadol is an analgesic medication 
.Also the sample had used tramadol in bad practice ,were the statistical result show 
that the sample were abused tramadol for un therapeutic way .Also the sample had 
attitude to stop abused tramadol and the main reason for this is healthy , and 




All the items symptom dimensions 









1 Knowledge of tramadol 
abusers 
4.09 0.413 81.86 26.482 0.000 
2 
Practices of tramadol abuse 
3.65 0.544 72.98 11.938 0.000 
3 
Attitudes  of tramadol abuse 
3.87 0.695 77.47 12.568 0.000 
4 The psychological state of the 
abusers of tramadol 
3.81 1.019 76.24 7.972 0.000 
5 The presence of side effects 
of the abuse of  tramadol. 
3.84 0.684 76.80 12.276 0.000 
 
All sections  
3.83 0.341 76.56 24.291 0.000 
Critical value of t at df "99" and significance level 0.05 equal 1.98 
 
Q1. Is there  a significant difference at α ≤ 0.05 among the respondents' answers 
regarding in (assess the abuse of tramadol among persons who have tramadol abuse 
by examine the level of knowledge, attitude, and practice )  due to demographic 
data (sex, Age, Address, Marital Status, Number of family members who live with 
you in the same house, Monthly income of NIS , Scientific level, Profession). 
And this question  divided into sub questions  as follows: 
1.1 Is there  a significant difference at α ≤ 0.05 among the respondents' answers 
regarding in (the assess the abuse of tramadol among persons who have tramadol 
abuse by examine the level of knowledge, attitude, and practice )  due to sex. 
To test the question we use the Independent Samples Test and the result illustrated in 
table no.(24) which shows the following results: the p-value  equal 0.569    which is 
greater than 0.05  and the absolute value of T test  equal  0.572 which  is less than the 
value of critical value which is equal 1.98, that‘s  means there is no  significant 
difference at α ≤ 0.05 among the respondents' answers regarding in (the assess the abuse 
of tramadol among persons who have tramadol abuse by examine the level of 
knowledge, attitude, and practice )  due to sex . This attribute that problem is very 






Independent Samples Test for difference among the respondents' answers regarding the 
assess the abuse of tramadol among persons who have tramadol abuse by examine the 
level of knowledge, attitude, and practice due to sex 






the assess the abuse of tramadol 
among persons who have tramadol 
abuse by examine the level of 
knowledge, attitude, and practice 
Male 
86 3.836 0.346 
0.572 0.569 
female 
14 3.780 0.315 
Critical value of t at df "98" and significance level 0.05 equal 1.98 
1.2-Is there  a significant difference at α ≤ 0.05 among the respondents' answers regarding 
(assess the abuse of tramadol among persons who have tramadol abuse by examine 
the level of knowledge, attitude, and practice )  due to Age. 
To test the question we use the one way ANOVA  test and the result illustrated in table 
no.(25) which shows the following results: the p-value  equal 0.744  which is greater 
than 0.05  and the value of  F test  equal  0.297  which  is less than the value of critical 
value which is equal 3.09 , that‘s  means There is no  significant difference at α ≤ 0.05 
among the respondents' answers regarding (assess the abuse of tramadol among persons who 
have tramadol abuse by examine the level of knowledge, attitude, and practice )  due to 
Age. This attribute that the abusers from young people .  
 
Table No.(25) 
One way ANOVA test for difference among the respondents' answers regarding 
among the (the assess the abuse of tramadol among persons who have tramadol 
abuse by examine the level of knowledge, attitude, and practice )  due to Age 










the assess the abuse of 
tramadol among persons who 
have tramadol abuse by 
examine the level of 
knowledge, attitude, and 
practice 
Between Groups 
0.070 2 0.035 
0.297 0.744 Within Groups 11.432 97 0.118 
Total 11.502 99  
Critical value of F at df "2,97" and significance level 0.05 equal 3.09 
1.3-Is there  a significant difference at α ≤ 0.05 among the respondents' answers regarding 
in (the assess the abuse of tramadol among persons who have tramadol abuse by 
examine the level of knowledge, attitude, and practice )  due to Address. 
To test the question we use the one way ANOVA  test and the result illustrated in table 
no.(26) which shows the following results: the p-value  equal  0.309 which is greater 
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than 0.05  and the value of  F test  equal 1.215   which  is less than the value of critical 
value which is equal 2.47 , that‘s  means There is no  significant difference at α ≤ 0.05 
among the respondents' answers regarding (the assess the abuse of tramadol among persons 
who have tramadol abuse by examine the level of knowledge, attitude, and practice )  
due to Address . This attribute that the problem is speared on all Gaza strip governorates  
Table No.(26) 
One way ANOVA test for difference among the respondents' answers regarding among 
the (assess the abuse of tramadol among persons who have tramadol abuse by examine the 
level of knowledge, attitude, and practice )  due to Address 










the assess the abuse of 
tramadol among persons who 
have tramadol abuse by 
examine the level of knowledge, 
attitude, and practice 
Between Groups 
0.560 4 0.140 
1.215 0.309 Within Groups 10.942 95 0.115 
Total 11.502 99  
Critical value of F at df "4,95" and significance level 0.05 equal 2.47 
1.4-Is there  a significant difference at α ≤ 0.05 among the respondents' answers regarding 
in (the assess the abuse of tramadol among persons who have tramadol abuse by 
examine the level of knowledge, attitude, and practice )  due to Marital Status.  
To test the question we use the one way ANOVA  test and the result illustrated in table 
no.(27) which shows the following results: the p-value  equal 0.632  which is greater 
than 0.05  and the value of  F test  equal 0.461   which  is less than the value of critical 
value which is equal 3.09 , that‘s  means There is no  significant difference at α ≤ 0.05 
among the respondents' answers regarding (the assess the abuse of tramadol among 
persons who have tramadol abuse by examine the level of knowledge, attitude, and 
practice )  due to Marital Status 
Table No.(27) 
One way ANOVA test for difference among the respondents' answers regarding among 
the (the assess the abuse of tramadol among persons who have tramadol abuse by examine 
the level of knowledge, attitude, and practice )  due to Marital Status. 










the assess the abuse of tramadol 
among persons who have 
tramadol abuse by examine the 
level of knowledge, attitude, and 
practice 
Between Groups 
0.108 2 0.054 
0.461 0.632 
Within Groups 11.394 97 0.117 
Total 11.502 99  
Critical value of F at df "2,97" and significance level 0.05 equal 3.09 
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1.5-Is there  a significant difference at α ≤ 0.05 among the respondents' answers 
regarding in (the assess the abuse of tramadol among persons who have tramadol 
abuse by examine the level of knowledge, attitude, and practice )  due to Number 
of family members who live with you in the same house. 
To test the question we use the one way ANOVA  test and the result illustrated in table 
no.(28) which shows the following results: the p-value  equal 06.03  which is greater 
than 0.05  and the value of  F test  equal   0.508 which  is less than the value of critical 
value which is equal 3.09 , that‘s  means There is no  significant difference at α ≤ 0.05 
among the respondents' answers regarding (the assess the abuse of tramadol among 
persons who have tramadol abuse by examine the level of knowledge, attitude, and 
practice )  due to Number of family members who live with you in the same house. 
Table No.(28) 
One way ANOVA test for difference among the respondents' answers regarding among 
the (the assess the abuse of tramadol among persons who have tramadol abuse by examine 
the level of knowledge, attitude, and practice )  due to Number of family members who 
live with you in the same house.            










the assess the abuse of tramadol 
among persons who have 
tramadol abuse by examine the 
level of knowledge, attitude, and 
practice 
Between Groups 
0.119 2 0.060 
0.508 0.603 
Within Groups 11.383 97 0.117 
Total 11.502 99  
Critical value of F at df "2,97" and significance level 0.05 equal 3.09 
1.6-Is there  a significant difference at α ≤ 0.05 among the respondents' answers regarding 
in (assess the abuse of tramadol among persons who have tramadol abuse by 
examine the level of knowledge, attitude, and practice )  due to Monthly income of 
NIS. 
To test the question we use the one way ANOVA  test and the result illustrated in table 
no.(29) which shows the following results: the p-value  equal  0.401which is greater 
than 0.05  and the value of  F test  equal  0.990  which  is less than the value of critical 
value which is equal 2.70 , that‘s  means There is no  significant difference at α ≤ 0.05 
among the respondents' answers regarding (the assess the abuse of tramadol among 
persons who have tramadol abuse by examine the level of knowledge, attitude, and 






One way ANOVA test for difference among the respondents' answers regarding among 
the (the assess the abuse of tramadol among persons who have tramadol abuse by examine 
the level of knowledge, attitude, and practice )  due to Monthly income of NIS 










the assess the abuse of tramadol 
among persons who have 
tramadol abuse by examine the 
level of knowledge, attitude, and 
practice 
Between Groups 
0.345 3 0.115 
0.990 0.401 
Within Groups 11.157 96 0.116 
Total 11.502 99  
Critical value of F at df "3,96" and significance level 0.05 equal 2.70 
 
 
1.7-Is there  a significant difference at α ≤ 0.05 among the respondents' answers 
regarding in (the assess the abuse of tramadol among persons who have tramadol 
abuse by examine the level of knowledge, attitude, and practice )  due to Scientific 
level. 
To test the question we use the one way ANOVA  test and the result illustrated in table 
no.(30) which shows the following results: the p-value  equal 0.088  which is greater 
than 0.05  and the value of  F test  equal  2.246  which  is less than the value of critical 
value which is equal 2.70  , that‘s  means There is no  significant difference at α ≤ 0.05 
among the respondents' answers regarding (the assess the abuse of tramadol among 
persons who have tramadol abuse by examine the level of knowledge, attitude, and 
practice )  due to Scientific level. 
Table No.(30) 
One way ANOVA test for difference among the respondents' answers regarding among 
the (the assess the abuse of tramadol among persons who have tramadol abuse by examine 
the level of knowledge, attitude, and practice )  due to Scientific level 










the assess the abuse of tramadol 
among persons who have 
tramadol abuse by examine the 
level of knowledge, attitude, and 
practice 
Between Groups 
0.754 3 0.251 
2.246 0.088 
Within Groups 10.748 96 0.112 
Total 11.502 99  
Critical value of F at df "3,96" and significance level 0.05 equal 2.70 
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1.8-Is there  a significant difference at α ≤ 0.05 among the respondents' answers regarding 
in (the assess the abuse of tramadol among persons who have tramadol abuse by 
examine the level of knowledge, attitude, and practice )  due to Profession. 
To test the question we use the one way ANOVA  test and the result illustrated in table 
no.(31) which shows the following results: the p-value  equal  0.014 which is greater 
than 0.05  and the value of  F test  equal  3.305  which  is less than the value of critical 
value which is equal 2.47 , that‘s  means There is a  significant difference at α ≤ 0.05 
among the respondents' answers regarding (the assess the abuse of tramadol among persons 
who have tramadol abuse by examine the level of knowledge, attitude, and practice )  
due to Profession, and Scheffe Multiple Comparisons test table no.(32) show that there in a 
difference between  " Worker " , and  " other Profession "  , and the difference  in favor of " 
Worker "   
Table No.(31) 
One way ANOVA test for difference among the respondents' answers regarding among the (the 
assess the abuse of tramadol among persons who have tramadol abuse by examine the level of 
knowledge, attitude, and practice )  due to Profession 










assess the abuse of tramadol 
among persons who have 
tramadol abuse by examine the 
level of knowledge, attitude, and 
practice 
Between Groups 
1.405 4 0.351 
3.305 0.014 Within Groups 10.097 95 0.106 
Total 11.502 99  
Critical value of F at df "4,95" and significance level 0.05 equal 2.47 
 
Table No.(32) 
Scheffe Multiple Comparisons test  
Mean Difference 
Profession 
Employee Worker Student Unemployed Others 
Employee 
 -0.278 -0.111 -0.069 0.161 
Worker 
0.278  0.167 0.209 0.439
* 
Student 
0.111 -0.167  0.042 0.272 
Unemployed 




-0.272 -0.230  






4.3 Daily Dose of tramadol   
Table No(33) explain the daily average dose of tramadol ,which abused by the study 
sample , it is different between person to person , the below table identify the mean of 
daily dose of tramadol which is 8 tablets from 225 mg . 
Table No.(33) 
"No" of tablet according to 
persons 
"No" of tablet that abused 
daily  
No" of Persons " 
10 5 2 
9 3 3 
48 12 4 
24 4 6 
91 13 7 
72 8 9 
117 9 13 
90 6 15 
133 7 19 































Chapter (Five): Conclusion and Recommendation                                    
5.1Conclusion                                                                                                                    
This study aims to assess the tramadol abuse among clients who are attending private 
psychiatric clinics in Gaza city by assessing the level of knowledge , attitude , and 
practice of abusers. It was descriptive, analytical and cross sectional study. Two private 
clinics were selected for the study . The target population of this study is all clients who 
are treated as tramadol abusers. The study excludes clients who are treated for other 
psychiatric disorders .The sample of this study was 100 clients were selected by taking 
4 clients from two clinics every day during one month . The response rate was 83%.The 
study tool was a self-administer questionnaire which has six categories ( knowledge , 
attitude , practice , psychological state , and the presence of side effects related to abuse 
of tramadol ) .                                                                                                                   
Male were more dominant in the study , the researcher attributed this dominance to the 
fact that women in Palestinian society are afraid of the stigma, especially knowing that 
the community is considered a conservative community. 42% of the sample were less 
than twenty five years old. These results come with the fact that the percentage of 
young people in Palestinian society is high, according to the Palestinian Center for 
Statistic. 57% of the sample were married, this can be explained by the finding that 
tramadol has an effect of prolong the time of sexual intercourse. 51% of  the sample 
were has low monthly income the researcher attributed that to the bad economic status 
in Gaza strip people . 36% of respondents hold a Bachelor degree which might be 
attributed to the low level of stigma associated with tramadol abuse compared to other 
substances such as cannabises and alcohol in Gaza Strip. Additionally tramadol abuse 
might provide a window for educated youth to escape from tough reality. 
                                                                                   
 5.1.1Knowledge   
96.40% of the sample believe that the abuse of tramadol, is a problem in the Gaza Strip 
94.8 % of the sample known that tramadol is medical drug use for analgesia .             
94.40% of the sample believe that abusing of tramadol cause addiction ,researcher 
attributed that the using of tramadol not for treatment but to at chive other goals.             
66% of the sample believe that work was affected due to using tramadol positively 
moderately.62.60% of the sample believe that work was affected due to using tramadol 
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negatively moderately . Researcher attributed that difference of doses between abusers. 
62.40% of the sample Believe that the abusing of tramadol is not religiously forbidden 
moderately , this attributed there is no religious guidance about tramadol .                         
In general the results for all  items of the field show that the average mean equal  4.09  
and the weight mean equal 81.86  % which is  greater  than  " 60%"  and the value of t 
test equal  26.482 which is greater than the critical value which is equal 1.98  and the p- 
value equal 0.000  which is less  than 0.05, that means the sample Believe that taking 
tramadol, affects the sexual life and the misusing tramadol is not religiously forbidden  
at significant    level 05.0 . 
 
5.1.2Practices 
The result show that 94.80%  of the sample get tramadol from friends , 92.60% of the 
sample use tramadol to reach the state of euphoria ,92.4% and to help them to delay 
ejaculation . 92.40% of  the sample  increase taking the number of pills from time to 
time  this approve that abuse of  tramadol cause addiction . Our study showed a strong 
association between smoking and tramadol abuse as around 80% of our sample was 
smokers. 
In  general the results for all  items of the field show that the average mean equal   3.65 
and the weight mean equal   72.98% which is  greater  than  " 60%"  and the value of t 
test equal  11.938 which is greater than the critical value which is equal 1.98  and the p- 
value equal 0.000  which is less  than 0.05, that means   that the samples abused 
tramadol with wrong Practices at a significant    level 05.0 . 
 
5.1.3Attitude  
The result show that 89.00% of the sample  reasons behind stopping the use of tramadol 
healthy ,researcher attributed that for high doses of tramadol ,and taken tramadol for 
non-medical cause . 87.60% of the sample support programs of mass media to stop the 
spared of this phenomena ,this attributed that may few media programs have 
constructed to explore the dangerous result of abuse tramadol The abuser haven't felt 
any embarrassment or stigma about abusing tramadol, this attributed the fast of speared 





5.1.4 Psychological state   
The most of sample have psychological stress ,anxiety , sleeping disorder , and abused 
tramadol to escape from there reality , this attributed that Israel occupation and siege 
and speared of unemployment  have the main effect of abusing tramadol .  
 
5.1.5 Presence of side effects 
Tramadol has side effect, most of the sample have complained about side effect , and it 
has varied between person to person and it depend on the volume of the dose .The more 
side effect is convulsion this attributed that the abuser has toxic dose, also the abuser 
has another side effect such as gastrointestinal disturbance ,irritability , physical 
symptom especially when the abuser stop taking tramadol . 
There is no  significant difference at α ≤ 0.05 among the respondents' answers regarding 
in (the assess the abuse of tramadol among persons who have tramadol abuse by 
examine the level of knowledge, attitude, and practice )  due to sex. There is no  
significant difference at α ≤ 0.05 among the respondents' answers regarding (the assess 
the abuse of tramadol among persons who have tramadol abuse by examine the level of 
knowledge, attitude, and practice )  due to Age. There is no  significant difference at α ≤ 
0.05 among the respondents' answers regarding (the assess the abuse of tramadol among 
persons who have tramadol abuse by examine the level of knowledge, attitude, and 
practice )  due to Address. There is no  significant difference at α ≤ 0.05 among the 
respondents' answers regarding (the assess the abuse of tramadol among persons who 
have tramadol abuse by examine the level of knowledge, attitude, and practice )  due to 
Marital Status. There is no  significant difference at α ≤ 0.05 among the respondents' 
answers regarding (the assess the abuse of tramadol among persons who have tramadol 
abuse by examine the level of knowledge, attitude, and practice )  due to Number of 
family members who live with you in the same house. There is no  significant difference 
at α ≤ 0.05 among the respondents' answers regarding (the assess the abuse of tramadol 
among persons who have tramadol abuse by examine the level of knowledge, attitude, 
and practice )  due to Monthly income of NIS. There is no  significant difference at α ≤ 
0.05 among the respondents' answers regarding (the assess the abuse of tramadol among 
persons who have tramadol abuse by examine the level of knowledge, attitude, and 
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practice )  due to Scientific level. There is a  significant difference at α ≤ 0.05 among the 
respondents' answers regarding (the assess the abuse of tramadol among persons who 
have tramadol abuse by examine the level of knowledge, attitude, and practice )  due to 
Profession, and Scheffe Multiple Comparisons test show that there in a difference 






















5.2   Recommendations 
 
1-Decision makers  should tighten controls on tunnels. 
2-  All authorities including political, social, academic and religious authorities should  
be engaged to know the reasons for the spread of this phenomenon. 
3- Legal bodies should enforce strict laws against drug dealers . 
4- Encourage media programs across various media, to educate people about the 
dangers of abuse of Tramadol. 
5-Organizing awareness campaigns against tramadol abuse at schools and universities    
6- Only licensed  pharmaceutical companies should be allowed for importing narcotic 
drugs. 
7-  Development of well-trained psychiatric clinics to deal with addicted people . 
8- Publication of books, brochures, flyers that address the problem of addiction. 
9- Dissemination of legal awareness and clear warning against tramadol use and   
marketing   
10- Dissemination of religious consciousness, and religious culture, and the 
consolidation of the social and educational values to the members of the community. 
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 5.3  Recommendations for Further Research 
- Further Studies to chemically analyze the substance of tramadol that enter 
through the tunnels .                                                                                           
- Further Studies for the work of rehabilitation programs for addicts.                     
- Further Studies to know the prevalence of addiction in Palestine .                      
- More objective studies to show the impact of tramadol abuse on personal 
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" Assessment of tramadol abuse among  clients who are attending  private 
psychiatric clinics-KAP  study. 
 
 
Brothers and sisters who are participating in the study. 
 
This study carried out by the researcher as a requirement for a master's degree in 
community mental health - the Islamic University. 
 
Researcher thanks  for your participation in this study by answering the questionnaire, 
which does not take more than 20 minutes of your valuable time and your participation 
contribute to the success of the study aimed to identify the knowledge, attitudes and 
practices of people who are  misused and abuse tramadol. 
 
Researcher would like to emphasize that the information will remain confidential and 
for the purpose of scientific research that does not need to mention names. 
Note that the right to refrain from participating answer any question or refused to 
participate. 
 
Thank you for participating. 
        Researcher 




 ثغُ هللا اٌشؽّٓ اٌشؽ١ُ
 




Please tick × in the appropriate box for you 
1-Age…………… 
2-Sex :         male               female           
3- Address : 
North governorate             Gaza governorate         
 Middle governorate           Khan yunis  governorate         
Rafah governorate  
4- Marital Status: 
Single                       Married               Widowed               Divorce   
5- Number of family members who live with you in the same           
house :……………………. 
6- Monthly income of NIS: 
Less than 1000 NIS         NIS 1000-2000           
NIS 2100-3000               3100 and above           
7- Scientific level: 
Less than High School          High School          
Diploma of two years            Bachelor                 up Graduate           
8- Profession : 
Employee            Worker            Student           Unemployed 
Others ……………………..            





















     Know tramadol.  DO you 9 
     Do you  Believe that the using of 
tramadol, is a problem in the Gaza 
Strip 
10 
     Do you Believe that there is a certain 
group misuses tramadol. 
 
11 
     Do you Believe that, taking tramadol 
affects the persons daily life  
 
12 




     Do you Believe that the widespread 




      Do you Believe that taking tramadol, 
affects the sexual life. 
 
15 
     Were you aware of this drug doses 
when you take it . 
 
16 
     Do you  Believe that the misuse of 
tramadol causes addiction. 
 
17 
     Did your  work was  affected due to 
using tramadol negatively .  
18 
     Did your work was affected due to 
using tramadol positively . 
 
19 
     Do you  Believe that the misusing 
tramadol is religiously for bidden. 
 
20 
     Do you  Believe that the smoking is 













agree   
Sentence N.o 
     Can you get tramadol from pharmacies 
easily . 
22 
     Can you get tramadol from drug 
dealers . 
23 
     Can you get tramadol from friends . 
 
24  
     Can you get tramadol from those who 
work in the tunnels  . 
25 
     Did you use tramadol to treat 
premature ejaculation . 
 
26 




     Did tramadol help you to take your 
time in delaying  ejaculation. 
 
28 
     Did you use tramadol while you did 
not suffer from premature ejaculation. 
 
29 




     Did you start taking pills of 100mg. 
 
31 
     Did you increase taking the number of 
pills from time to time  . 
 
32 
     Did you use tramadol to reach the state 
of euphoria . 
33 
     Did you use tramadol to help you in 






     Did you take tramadol at the same 


















     Did the effect of tramadol was 
affected with the amount and the 
number of pills . 
 
37 
     Did you use tramadol  to help in your 
study. 
38 
     Did you use tramadol to help you in 








     Are you smoking . 41 
     Are you a heavy smoker . 42 
     Did the use of tramadol affect in 
increasing the number of cigarettes 
and change the euphoria of smoking. 
 
43 
     Do you take alcoholic drinks 
 
44 
     Did you misuse another drug with 
tramadol. 
45 
Attitudes  of tramadol abusers. 
 
     Do you Support the measures of 




     Do you support programs of mass 




     Did you  try to stop the using tramadol 















     Did you try stop using tramadol due to 
the hardness of getting it. 
 
49 
     Did you feel of  the stigma because of 
taking   tramadol . 
 
50 
     Was there any one who expected that 
you were taking tramadol . 
51 
     Did any one around you suffer from 
your taking tramadol . 
 
52 
     Did you neglect your family because 
of using tramadol . 
 
53 
     Were you exposed to confrontation or 
embarrassments due to taking 
tramadol .  
 
54 
     Did you  Try to stop on your own. 
 
55 




     Were you Committed to the 
instructions of the treatment program. 
 
57 
     Were you able to get rid of the using 
tramadol for more than a month. 
 
58 




     Are the  reasons behind stopping the 
use of tramadol, religious. 
 
60 
      Are the  reasons behind stopping the 
use of tramadol social . 
61 
     Are the  reasons behind stopping the 
use of tramadol economic . 
62 
     Are the  reasons behind stopping the 














     Did you take this drug while you were 
 suffering from psychological stress. 
 
64 
     Were  you suffering  from anxiety. 
 
65 




     Did you deal with tramadol to escape 
from reality . 
 
67 




The presence of side effects related to tramadol abuse. 
     Did you  suffered from gastrointestinal 
disorders that  caused by misuse  of 
tramadol .  
69 
     Did you  suffer from convulsions or 




     Did you  Suffer  from itching  feeling 
in the feet or electrical waves during 
the misusing tramadol.    
 
71 
     Did you  Suffer  from a rise in body 
temperature during the misuse of 
tramadol . 
72 
     Did you  Suffer  from tremor when 
you did not use tramadol .  
 
73 
     Did you feel dizzy while you were 




     Did you have  physical symptoms 







     Did you have  high blood pressure 




     Did you have  excessive sweating 











79 - Have you experienced any symptoms during the use of tramadol, or 


























 ِبي"ا"ِؼشفخ ٚعٍٛن ِّٚبسعبد االشخبص اٌز٠ٓ اعبؤٚا اعزخذاَ ػمبس اٌزش
 
 اإلخٛح ٚ ا٤خٛاد اٌّشبسو١ٓ فٟ اٌذساعخ.
 
٘زٖ اٌذساعخ ٠مَٛ ثٙب اٌجبؽش وّزطٍت ٌٍؾظٛي ػٍٝ دسعخ اٌّبعغز١ش فٟ اٌظؾخ إٌفغ١خ 
 اٌغبِؼخ االعال١ِخ .–اٌّغزّؼ١خ 
 
شىش اٌجبؽش ٌىُ ؽغٓ اٌّشبسوخ فٟ ٘زٖ اٌذساعخ ِٓ خالي اإلعبثخ ػٍٝ أعئٍخ االعزج١بْ ٚاٌزٟ ال ٠
دل١مخ ِٓ ٚلزىُ اٌض١ّٓ ٚاْ ِشبسوزىُ رغُٙ فٟ ئٔغبػ اٌذساعخ اٌزٟ رٙذف  02رغزغشق اوضش ِٓ 
 ٌٍزؼشف ػٍٝ ِؼشفخ ٚعٍٛن ِّٚبسعبد االشخبص اٌز٠ٓ اعبؤٚا اعزخذاَ ٚرؼبؽٝ ػمبس اٌزشاِبي .
 
٠ٛد اٌجبؽش اٌزأو١ذ ػٍٝ أْ اٌّؼٍِٛبد عزجمٝ عش٠خ ٚ ٌٙذف اٌجؾش اٌؼٍّٟ ٌزٌه ال داػٟ ٌزوش 
 ا٤عّبء.
 ػٍّب ثأٔٗ ِٓ ؽك اٌّشبسن االِزٕبع ػٓ ئعبثخ أٞ عإاي أٚ سفغ اٌّشبسوخ.
 
 شىشا ٌىُ ػٍٝ اٌّشبسوخ 
 
 اٌجبؽش                                                                                             





 ثغُ هللا اٌشؽّٓ اٌشؽ١ُ
 سلُ االعزج١بْ               .................................................................خبص ثبٌجبؽش                
 اٌج١بٔبد اٌشخظ١خ 
 
 شثغ إٌّبعت ٌه/ٜفٟ اٌّ× ِٓ فؼٍه ػغ/ٜ ئشبسح 
 عٕخ----------------اٌؼّش-1
 اٌغٕظ:            روش                        أٔضٝ-0
 اٌؼٕٛاْ -3
 ِؾبفظخ  اٌشّبي                           ِؾبفظخ غضح                         ِؾبفظخ اٌٛعطٝ  
 ؼِؾبفظخ سف  ٠ٛٔظ                       ِؾبفظخ خبْ  
 
 اٌؾبٌخ االعزّبػ١خ:-4
 ا أػضة/ آٔغخ                                             ِزضٚط/ ح        
 أسًِ/ ح                                                  ِطٍك/ ح        
 
 .---------------ػذد أفشاد ا٤عشح اٌز٠ٓ ٠م١ّْٛ ِؼه فٟ ٔفظ اٌغىٓ:-5
 ٙشٞ ثبٌش١ىً:اٌذخً اٌش-6
               3222-0122ش١ىً         0222-1222ش١ىً          1222ألً ِٓ         
 
 فأوضش  3122         
 الوستىي العلوي: -7
 ألً ِٓ صب٠ٛٔخ ػبِخ                             صب٠ٛٔخ ػبِخ                                
 ٠ٛخ اٌؼبِخ                  ثىبٌٛس٠ٛط         دساعبد ػ١ٍب .     دثٍَٛ عٕز١ٓ ثؼذ اٌضبٔ     
 إٌّٙخ:-8







 هعرفت هسيئ استخذام عقار التراهال.  
هىافق  العبارة الرقن
 بشذة





      .رؼشف/ٜ ػمبس اٌزشاِبي 9
      .رؼزمذ/ٜ أْ رؼبؽٟ اٌزشاِبي ِشىٍخ فٟ لطبع غضح 01
      .رؼزمذ/ٜ أْ ٕ٘بن فئخ ِؼ١ٕخ رزؼبؽٝ اٌزشاِبي 00
رؼزمذ/ٜ أْ رٕبٚي ػمبس اٌزشاِبي ٠إصش فٟ ِغبس اٌشخض ا١ٌَٛ  01
 .ا١ٌِٟٛ
     
      .بسح ػٓ ِغىٓ ٣ٌالَرؼشف/ٜ أْ ػمبس اٌزشاِبي ٘ٛ ػج 02
      .رؼزمذ/ٜ أْ ٌٍؾظبس اصش فٟ أزشبس رؼبؽٝ ٘زا اٌؼمبس 03
      .رؼزمذ/ٜ أْ رٕبٚي اٌزشاِبي ٠إصش فٟ اٌؾ١بح اٌغٕغ١خ 04
      وٕذ/ٜ ػٍٝ ػٍُ ثغشػبد ٘زا  اٌؼمبس ػٕذ رٕبٌٚه ٌٗ . 05
      .رؼزمذ /ٜ أْ رؼبؽٟ ٘زا اٌؼمبس ٠غجت اإلدِبْ 07
      . رأصش ػٍّه/ٜ ثغجت اعزخذاِه اٌزشاِبي ثظٛسح عٍج١خ 01
      . رأصش ػٍّه/ٜ ثغجت اعزخذاِه ٌٍزشاِبي ثظٛسح ا٠غبث١خ 09
      رؼزمذ/ٜ أْ رؼبؽٟ اٌزشاِبي ؽشاَ ششػب . 11
      رؼزمذ/ٜ اْ اٌزذخ١ٓ ؽشاَ ششػب . 10
 هوارساث هسيئ استخذام التراهال .
هىافق  العبارة الرقن
 بشذة





      ٠زُ اٌؾظٛي ػٍٝ اٌؼمبس ِٓ خالي اٌظ١ذ١ٌبد . 11
      اٌؾظٛي ػٍٝ اٌؼمبس ِٓ رغبس اٌّخذساد . 12
      اٌؾظٛي ػٍٝ اٌؼمبس ِٓ ا٤طذلبء . 13
      اٌؾظٛي ػٍٝ اٌؼمبس ِّٓ ٠ؼًّ فٟ ا٤ٔفبق . 14
 ػالط اٌمزف اٌّجىش . ً٘ رٕبٌٚذ اٌؼمبس ِٓ اعً 15
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هىافق  العبارة الرقن
 بشذة





      ً٘ عبػذن اٌؼمبس فٟ رأخ١ش اٌمزف . 17
ً٘ عبػذن اٌؼمبس فٟ اٌؾظٛي ػٍٝ اٌّذح اٌّطٍٛثخ فٟ رأخ١ش  11
 اٌمزف
     
      رٕبٌٚذ اٌؼمبس ٚأٔذ ال رؼبٔٝ ِٓ اٌمزف اٌّجىش . 19
      رٕبٌٚذ/ٜ ٘زا اٌؼمبس ِٓ اعً اٌغٙش ٌّذح ؽ٠ٍٛخ . 21
      ٍِغُ .122ثذأد/ٜ ثزٕبٚي ؽجبد ِٓ ػ١بس 20
      لّذ/ٜ ثض٠بدح ػذد اٌؾجبد ث١ٓ اٌفزشح ٚاالخشٜ . 21
      رٕبٌٚذ ٘زا اٌؼمبس ٌٍؾظٛي ػٍٝ ؽبٌخ ِٓ إٌشٛح ٚاٌظٍٍٙخ . 22
      فٟ ػٍّه . رٕبٌٚذ/ٜ ٘زا اٌؼمبس ِٓ اعً ِغبػذره 23
      وٕذ/ٜ رزٕبٚي اٌؼمبس فٟ ٔفظ ٚلذ آخش عشػخ . 24
      . لّذ/ٜ ثأػّبي غ١ش لب١ٔٛٔخ ٌٍؾظٛي ػٍٝ اٌزشاِبي 25
      ص٠بدح رأص١ش اٌؼمبس وبٔذ رزأصش ثؾغُ اٌغشػخ ٚػذد اٌؾجبد . 27
      رٕبٌٚذ/ٜ اٌزشاِبي ِٓ اعً ِغبػذره فٟ اٌذساعخ . 21
اٌزشاِبي ِٓ اعً ِغبػذره فٟ اٌغٙذ اٌجذٟٔ ٌٍؾفالد رٕبٌٚذ/ٜ  29
. 
     
      رٕبٌٚزٝ اٌؼمبس أصٕبء فزشح اٌؾًّ . 31
      ً٘ أذ/ٜ ِذخٓ ٌٍغغبئش . 30
      رؼزجش/ٜ ِذخٓ ثشىً وج١ش ٌٍغغبئش . 31
اصش اعزخذاِه/ٜ ٌٍؼمبس فٟ ص٠بدح ػذد اٌغغبئش ٚرغ١ش ٔشٛح  32
 اٌزذخ١ٓ .
     
      بٚي/ٜ اٌّششٚثبد اٌىؾ١ٌٛخ .ً٘ رزٕ 33
      .أعأد/ٜ اعزخذاَ ػمبس ِظبؽت ٌؼمبس اٌزشاِبي 34
 تىجهاث هسيئ استخذام التراهال .
 ِٛافك اٌؼجبسح الرقن
 ثشذح





      .رإ٠ذ/ٜ ئعشاءاد اٌغٙبد اٌّؼ١ٕخ ٌٛلف أزشبس ٘زٖ اٌظب٘شح 35
122 
 
      .د ثشاِظ ئػال١ِخ ٌٛلف ٘زٖ اٌظب٘شحرإ٠ذ/ٜ ٚعٛ 37
ؽبٌٚذ/ٜ اٌزٛلف ػٓ اعزخذاَ اٌزشاِبي ثغجت اٌظشٚف  31
 .اٌّؾ١طخ
     
      ؽبٌٚذ/ٜ اٌزٛلف ػٓ اٌزشاِبي ثغجت طؼٛثخ اٌؾظٛي ػ١ٍخ . 39
      .ً٘ شؼشد/ٜ ثبٌٛطّخ ٌزٕبٚي اٌزشاِبي 41
      . رٛلغ ِٓ ؽٌٛه/ٜ رؼبؽ١ه ٌٍزشاِبي 40
      . بٔٝ ِٓ ؽٌٛه/ٜ العزخذاِه اٌزشاِبيػ 41
      .أٍّ٘ذ/ٜ ػبئٍزه العزخذاِه ٌٍزشاِبي 42
رؼشػذ/ٜ ٌٛعٛد ِٛاعٙبد أٚ اؽشاعبد العزخذاِه  43
 .ٌٍزشاِبي
     
      . ؽبٌٚذ/ٜ اٌزٛلف ثّفشدن 44
      . أخشؽذ/ٜ فٟ ثشٔبِظ ػالعٟ 45
      اٌزضِذ/ٜ ثزؼ١ٍّبد اٌجشٔبِظ اٌؼالعٟ . 47
      اعزطؼذ/ٜ اٌزخٍض ِٓ رؼبؽٟ اٌزشاِبي ٌّذح أوضش ِٓ شٙش . 41
      ٔغؾذ/ٜ فٟ اٌزٛلف ػٓ رؼبؽٝ اٌؼمبس . 49
      . دينيتا٤عجبة اٌزٟ دفؼزه ٌٍزٛلف ػٓ اعزخذاَ اٌزشاِبي  51
      اجتواعيت . ا٤عجبة اٌزٟ دفؼزه ٌٍزٛلف ػٓ اعزخذاَ اٌزشاِبي 50
      اقتصاديت . ا٤عجبة اٌزٟ دفؼزه ٌٍزٛلف ػٓ اعزخذاَ اٌزشاِبي 51
      صحيت . ا٤عجبة اٌزٟ دفؼزه ٌٍزٛلف ػٓ اعزخذاَ اٌزشاِبي 52
 الحالت النفسيت لوسيء استخذام عقار التراهال .
      ػٕذ رٕبٌٚه/ٜ ٌٙزا اٌؼمبس وٕذ رؼبٔٝ ِٓ ػغٛؽ ٔفغ١خ . 53
      ك .ً٘ وٕذ/ٜ رؼبٔٝ ِٓ اٌمٍ 54
      ً٘ وٕذ/ٜ رؼبٔٝ ِٓ اػطشاة فٟ إٌَٛ . 55
      رٕبٌٚذ/ٜ ػمبس اٌزشاِبي ٌٍٙشٚة ِٓ ٚالؼه . 57








 وجىد أعراض جانبيت إلساءة استخذام التراهال .
هىافق  العبارة الرقن
 بشذة





      . ٌزؼبؽ١ه اٌزشاِبي ػب١ٔذ/ٜ ِٓ اػطشاثبد ِؼ٠ٛخ 59
      ػب١ٔذ/ٜ ِٓ رشٕغبد اٚ اغّبءاد ٌزؼبؽ١ه اٌزشاِبي . 71
ػب١ٔذ/ٜ ِٓ ؽىخ فٟ اٌمذ١ِٓ اٚ شؼٛس ثّبط وٙشثٟ   70
 ٌزؼبؽ١ه اٌزشاِبي.
     
ػب١ٔذ/ٜ ِٓ اسرفبع فٟ دسعخ ؽشاسح اٌغغُ أصٕبء رؼبؽ١ه  71
 ٌٍزشاِبي.  
     
      ػب١ٔذ/ٜ ِٓ سعفخ ٌؼذَ رٕبٌٚه ٌؼمبس اٌزشاِبي . 72
      ػب١ٔذ/ٜ ِٓ دٚخخ أصٕبء رٕبٌٚه ٌؼمبس اٌزشاِبي . 73
      ػٕذ رٛلفه ػٓ اخز اٌزشاِبي ػب١ٔذ ِٓ أػشاع عغّب١ٔخ . 74
      ػٕذ رٛلفه ػٓ اخز اٌزشاِبي ػب١ٔذ ِٓ اسرفبع فٟ ػغؾ اٌذَ . 75
      ٕذ رٛلفه ػٓ اخز اٌزشاِبي ػب١ٔذ ِٓ اٌزؼشق .ػ 77
 



















Panel of expert 
  
The questionnaire were examined by a group of experts. Some items 
were added, modified or excluded as a result of their comments .  
 
 
1-Dr .Youssef ALjeesh . 
2- Dr .Abed ALkareem  Radwan . 
3-Dr .Mohammed Abu Sebah . 
4-Dr .Nafez Barakat . 

















٠ب اٌزٟ رإسف اٌؼبٌُ ثأعشح ٌٚمذ ظٙشد فٟ ا٢ٚٔخ ال شه اْ لؼ١خ اٌّخذساد ٚاالدِبْ ػ١ٍٙب رؼزجش ِٓ اٌمؼب
ػمبس ِغىٓ ٣ٌالَ  ١٘ذسٚوٍٛس٠ه٠ؼزجش اٌزشاِبدٚي  .االخ١شح  ظب٘شح أزشبس اعبءح اعزخذاَ ػمبس اٌزشاِبدٚي 
االخ١شح ِخبٚف ػب١ٌّخ ثشبْ  ا٢ٚٔخ. ٚرجشص فٟ اٌّشوضٞ اٌؼظجٟاٌّزٛعطخ ٚاٌشذ٠ذح ٚ٘ٛ ٠ؼًّ ػٍٝ اٌغٙبص 
 ٚي .ادِبْ اٌزشاِبد
 أهذاف الذراست : 
, ٚاٌز٠ٓ فٟ ِذ٠ٕخ غضح وبْ اٌٙذف اٌؼبَ ٌٙزٖ اٌذساعخ  ٘ٛ دساعخ رم١ّ١١خ ٌٍّشاعؼ١ٓ ٌٍؼ١بداد إٌفغ١خ اٌخبطخ 
٠زؼبٌغْٛ ِٓ االدِبْ ػٍٝ ػمبس اٌزشاِبدٚي , ٚلذ ا٘زُ اٌجبؽش ثذساعخ ِذٜ ِؼشفخ ػ١ٕخ اٌذساعخ ثبٌزشاِبدٚي , 
عزخذاَ ٘زا اٌؼمبس , ٚرٛعٙبرُٙ ؽٛي اعبءح اعزخذاَ ٘زا اٌؼمبس , ٚا٠ؼب رُ رغ١ٍؾ ٚو١ف وبٔذ ِّبسعزُٙ فٟ اعبءح ا
اٚ ػٕذ  ,اٌؼٛء ػٍٝ اٌؾبٌخ إٌفغ١خ ٌؼ١ٕخ اٌذساعخ , ًٚ٘ ػبٔٛا ِٓ رأص١شاد عبٔج١خ إلعبءح اعزخذاَ ٘زا اٌؼمبس
 . اٌزٛلف ػٓ اخزح
 هنهجيت الذراست :
ِؼذي االعزغبثخ ٌذٜ اٌّشبسو١ٓ  فٟ ٘زٖ اٌذساعخ  ٚوبِْغزؼشػخ  وبٔذ اٌذساعخ ٚطف١خ , رؾ١ٍ١ٍخ ,
ِش٠غ ػ١ٕخ ٌٙزٖ اٌذساعخ ؽ١ش رُ اخز اسثغ ِشػٝ  ١ِٛ٠ب ِٓ ػ١بدر١ٓ خبطز١ٓ  100, رُ اخز %83.3ؽٛاٌٝ
 ٚرٌه خالي شٙش .
لبَ اٌجبؽش ثجٕبء اداح اٌجؾش , ؽ١ش أٙب وبٔذ رزّضً فٟ عزخ ِؾبٚس ) اٌؼٛاًِ اٌذ٠ّٛغشاف١خ , ِغزٜٛ اٌّؼشفخ 
,اٌّّبسعبد , اٌزٛعٙبد , اٌؾبٌخ إٌفغ١خ , ٚعٛد اصبس عبٔج١خ , ٌّغٟء اعزخذاَ ػمبس اٌزشاِبدٚي (. رُ عّغ 
 .2. 8633اٌفب ِشرفؼخ ؽ١ش وبٔذ  وشٚ ٔجبؿاٌّؼٍِٛبد ػٓ ؽش٠ك االعزج١بْ ٚوبْ ٔغجخ اٌظذق ٚاٌضجبد 
 اهن النتائج :
وجغٛالد ِٓ  ثأخز ثذأٚا, ٚأُٙ   % ِٓ فئخ االٔبس14,% ِٓ اٌؼ١ٕخ ُ٘ ِٓ فئخ اٌزوٛس  86اظٙشد إٌزبئظ اْ * 
ٍِغُ  622 -٠422شبس اٌٝ اْ اٌغشػخ اٌذٚائ١خ ٟ٘ ),ٍِغُ ١ِٛ٠ب 1822ٍِغُ ؽزٝ ٚطٍٛا اٌٝ ؽذ 122ػ١بس 
 ١ِٛ٠ب( 
 .لطبع غضح فٟ% ِٓ اٌؼ١ٕخ ٠ؼزمذْٚ اْ اعبءح اعزخذاَ ػمبس اٌزشاِبدٚي ِشىٍخ 76ظٙشد إٌزبئظ اْ أ*
   . % ٠ذسوْٛ اْ اٌزشاِبدٚي ٠غجت االدِب74.4ْظ اْظٙشد إٌزبئأ *
 % ِٓ اٌؼ١ٕخ وبٔٛا ِذخ١ٕٓ .82* أظٙشد إٌزبئظ اْ 
 % اعزخذِٛا اٌزشاِبدٚي ٌٍؾظٛي ػٍٝ ؽبٌخ ِٓ إٌشٛح .70.4* أظٙشد إٌزبئظ اْ 
 %  اعزخذِٛا اٌزشاِبدٚي ٌّغبػذرُٙ فٟ رأخ١ش اٌمزف . 87.4* أظٙشد إٌزبئظ اْ 
 % ٌغأٚا اٌٝ ؽشق غ١ش لب١ٔٛٔخ ٌٍؾظٛي ػٍٝ اٌزشاِبدٚي . 63.4ئظ اْ ظٙشد إٌزبأ* 
 % وبٔٛا ٠ؼبٔٛا ِٓ اػطشاثبد ٔفغ١خ .86.04ظٙشد إٌزبئظ اْ أ* 
 % ػبٔٛا ِٓ اػشاع أغؾبث١ٗ ػٕذ رٛلفُٙ ػٓ اعزخذاَ اٌزشاِبدٚي . 72ظٙشد إٌزبئظ اْ أ* 
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 اعبءح اعزخذاَ اٌزشاِبدٚي .% ػبٔٛا ِٓ ٔٛثبد رشٕظ ثغجت  81.8* اظٙشد إٌزبئظ اْ 
 ِٓ ؽ١ش إٌّٙخ ٌظبٌؼ اٌؼّبي. α 2.25≥ دالٌخ * اظٙشد إٌزبئظ اْ ٕ٘بن فشٚق راد دالٌخ اؽظبئ١خ ػٕذ ِغزٜٛ 
 
 
 
 
 
 
